BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61-74. [PMID: 20175034 DOI: 10.1055/s-0030-1247133] [Cited by in Crossref: 657] [Cited by in F6Publishing: 632] [Article Influence: 59.7] [Reference Citation Analysis]
Number Citing Articles
1 Golfieri R, Bargellini I, Spreafico C, Trevisani F. Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. Liver Cancer 2019;8:78-91. [PMID: 31019899 DOI: 10.1159/000489791] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
2 Brehmer K, Brismar TB, Morsbach F, Svensson A, Stål P, Tzortzakakis A, Voulgarakis N, Fischer MA. Triple Arterial Phase CT of the Liver with Radiation Dose Equivalent to That of Single Arterial Phase CT: Initial Experience. Radiology 2018;289:111-8. [DOI: 10.1148/radiol.2018172875] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
3 Rinaldi L, Perrella A, Guarino M, De Luca M, Piai G, Coppola N, Pafundi PC, Ciardiello F, Fasano M, Martinelli E, Valente G, Nevola R, Monari C, Miglioresi L, Guerrera B, Berretta M, Sasso FC, Morisco F, Izzi A, Adinolfi LE. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. J Transl Med 2019;17:292. [PMID: 31462268 DOI: 10.1186/s12967-019-2033-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
4 Park Y, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yeon JE, Byun KS, Kim HS, Kim JH, Kim SU. Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. BMC Cancer 2019;19:363. [PMID: 30991968 DOI: 10.1186/s12885-019-5495-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
5 Liu L, Chen H, Wang M, Zhao Y, Cai G, Qi X, Han G. Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PLoS One. 2014;9:e91124. [PMID: 24651044 DOI: 10.1371/journal.pone.0091124] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 8.6] [Reference Citation Analysis]
6 Xiang X, Hu D, Jin Z, Liu P, Lin H. Radiofrequency Ablation vs. Surgical Resection for Small Early-Stage Primary Intrahepatic Cholangiocarcinoma. Front Oncol 2020;10:540662. [PMID: 33134161 DOI: 10.3389/fonc.2020.540662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lewis AL, Holden RR. DC Bead embolic drug-eluting bead: clinical application in the locoregional treatment of tumours. Expert Opin Drug Deliv. 2011;8:153-169. [PMID: 21222553 DOI: 10.1517/17425247.2011.545388] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
8 Sherman M. Design and Endpoints of Clinical Trials, Current and Future. Dig Dis Sci 2019;64:1050-7. [PMID: 30830522 DOI: 10.1007/s10620-019-05541-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Kim GA, Seock CH, Park JW, An J, Lee KS, Yang JE, Lim YS, Kim KM, Shim JH, Lee D. Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. Liver Int. 2015;35:232-239. [PMID: 24576055 DOI: 10.1111/liv.12516] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
10 Xu J, Wang Y, Zhang Y, Dang S, He S. Astemizole promotes the anti-tumor effect of vitamin D through inhibiting miR-125a-5p-meidated regulation of VDR in HCC. Biomed Pharmacother 2018;107:1682-91. [PMID: 30257386 DOI: 10.1016/j.biopha.2018.08.153] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
11 Morise Z, Kawabe N, Tomishige H, Nagata H, Kawase J, Arakawa S, Yoshida R, Isetani M. Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol 2014; 20(39): 14381-14392 [PMID: 25339825 DOI: 10.3748/wjg.v20.i39.14381] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 47] [Article Influence: 7.0] [Reference Citation Analysis]
12 Brunsing RL, Fowler KJ, Yokoo T, Cunha GM, Sirlin CB, Marks RM. Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI. Hepatoma Res 2020;6:59. [PMID: 33381651 DOI: 10.20517/2394-5079.2020.50] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
13 Yoo JJ, Lee JH, Lee SH, Lee M, Lee DH, Cho Y, Lee YB, Yu SJ, Kim HC, Kim YJ, Yoon JH, Kim CY, Lee HS. Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases. PLoS One. 2014;9:e113926. [PMID: 25427152 DOI: 10.1371/journal.pone.0113926] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
14 Hammond JS, Guha IN, Beckingham IJ, Lobo DN. Prediction, prevention and management of postresection liver failure. British Journal of Surgery 2011;98:1188-200. [DOI: 10.1002/bjs.7630] [Cited by in Crossref: 115] [Cited by in F6Publishing: 105] [Article Influence: 11.5] [Reference Citation Analysis]
15 Mohkam K, Rayar M, Adam JP, Muscari F, Rode A, Merle P, Pradat P, Bauler S, Delfour I, Chiche L, Ducerf C, Boudjema K, Lesurtel M, Laurent C, Mabrut JY. Evaluation of postoperative ascites after somatostatin infusion following hepatectomy for hepatocellular carcinoma by laparotomy: a multicenter randomized double-blind controlled trial (SOMAPROTECT). BMC Cancer 2018;18:844. [PMID: 30139340 DOI: 10.1186/s12885-018-4667-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Lee SH, Kim SU, Jang JW, Bae SH, Lee S, Kim BK, Park JY, Kim DY, Ahn SH, Han KH. Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma. Onco Targets Ther 2015;8:347-56. [PMID: 25678801 DOI: 10.2147/OTT.S75077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
17 Lindnér P, Holmberg E, Rizell M, Hafström L. Staging and therapy for patients with hepatocellular cancer in a defined population from 2000 to 2011 – active palliative treatment improved overall survival. Acta Oncologica 2016;55:297-302. [DOI: 10.3109/0284186x.2015.1080857] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Tomimaru Y, Eguchi H, Gotoh K, Kawamoto K, Wada H, Asaoka T, Noda T, Yamada D, Ogawa H, Umeshita K, Nagano H, Doki Y, Mori M. Platelet count is more useful for predicting posthepatectomy liver failure at surgery for hepatocellular carcinoma than indocyanine green clearance test: Platelet and ICG for Predicting PHLF. J Surg Oncol 2016;113:565-9. [DOI: 10.1002/jso.24166] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
19 Shen J, Wen J, Li C, Wen T, Yan L, Li B, Yang J, Lu C. The prognostic value of microvascular invasion in early-intermediate stage hepatocelluar carcinoma: a propensity score matching analysis. BMC Cancer 2018;18:278. [PMID: 29530006 DOI: 10.1186/s12885-018-4196-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
20 Bai K, Cao Y, Huang C, Chen J, Zhang X, Jiang Y. Association of Histone Methyltransferase G9a and Overall Survival After Liver Resection of Patients With Hepatocellular Carcinoma With a Median Observation of 40 Months. Medicine (Baltimore) 2016;95:e2493. [PMID: 26765460 DOI: 10.1097/MD.0000000000002493] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
21 Chang WT, Kao WY, Chau GY, Su CW, Lei HJ, Wu JC, Hsia CY, Lui WY, King KL, Lee SD. Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection? Surgery. 2012;152:809-820. [PMID: 22766361 DOI: 10.1016/j.surg.2012.03.024] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 6.8] [Reference Citation Analysis]
22 Stillström D, Beermann M, Engstrand J, Freedman J, Nilsson H. Initial experience with irreversible electroporation of liver tumours. Eur J Radiol Open 2019;6:62-7. [PMID: 30723754 DOI: 10.1016/j.ejro.2019.01.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
23 Mcevoy SH, Mccarthy CJ, Lavelle LP, Moran DE, Cantwell CP, Skehan SJ, Gibney RG, Malone DE. Hepatocellular Carcinoma: Illustrated Guide to Systematic Radiologic Diagnosis and Staging According to Guidelines of the American Association for the Study of Liver Diseases. RadioGraphics 2013;33:1653-68. [DOI: 10.1148/rg.336125104] [Cited by in Crossref: 62] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
24 Colombo M, Sangiovanni A. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2015;35 Suppl 1:129-138. [PMID: 25529098 DOI: 10.1111/liv.12713] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 6.2] [Reference Citation Analysis]
25 Llop E, Berzigotti A, Reig M, Erice E, Reverter E, Seijo S, Abraldes JG, Bruix J, Bosch J, García-pagan JC. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. Journal of Hepatology 2012;56:103-8. [DOI: 10.1016/j.jhep.2011.06.027] [Cited by in Crossref: 101] [Cited by in F6Publishing: 82] [Article Influence: 11.2] [Reference Citation Analysis]
26 Nam SW, Park KC, Choi HS, Lee B, Kim SW. Identification of Zinc Finger, MYM-type 2 (ZMYM2) as a regulator of sorafenib resistance in hepatocellular carcinoma cell lines. J Gastroenterol Hepatol 2014;29:633-9. [PMID: 24716227 DOI: 10.1111/jgh.12414] [Reference Citation Analysis]
27 Morise Z. Developments and perspectives of laparoscopic liver resection in the treatment of hepatocellular carcinoma. Surg Today 2019;49:649-55. [PMID: 30649611 DOI: 10.1007/s00595-019-1765-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Mizandari M, Azrumelashvili T, Paksashvili N, Kikodze N, Pantsulaia Ia, Janikashvili N, Chikovani T. Tumor Regression in HCC Patient with Portal Vein Tumor Thrombosis after Intraportal Radiofrequency Thermal Ablation. Case Reports Hepatol 2016;2016:6843121. [PMID: 27579192 DOI: 10.1155/2016/6843121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
29 Kim GA, Kim HI, Chang S, An J, Lee D, Lee HC, Han S, Shim JH. A Prospective Evaluation of the Reliability and Utility of Quality of Life Measures in Patients With Hepatocellular Carcinoma. Am J Clin Oncol 2019;42:555-63. [PMID: 31135382 DOI: 10.1097/COC.0000000000000555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Fan HL, Hsieh CB, Chang WC, Huang SH, Chan DC, Yu JC, Chu CH, Chen TW. Advanced age is not a contraindication for liver resection in cases of large hepatocellular carcinoma. Eur J Surg Oncol 2014;40:214-9. [PMID: 24316111 DOI: 10.1016/j.ejso.2013.10.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
31 Park Y, Park Y, Lim HS, Kim YS, Hong DJ, Kim HS. Soluble human leukocyte antigen-G expression in hepatitis B virus infection and hepatocellular carcinoma. Tissue Antigens. 2012;79:97-103. [PMID: 22136460 DOI: 10.1111/j.1399-0039.2011.01814.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
32 Zhu Q, Li N, Zeng X, Han Q, Li F, Yang C, Lv Y, Zhou Z, Liu Z. Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget. 2015;6:4440-4450. [PMID: 25686836 DOI: 10.18632/oncotarget.2913] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
33 Kalra N, Kang M, Duseja AK, Bhatia A, Singh V, Dhiman RK, Rajwanshi A, Chawla YK, Khandelwal N. Comparison of radiofrequency ablation alone & in combination with percutaneous ethanol injection for management of hepatocellular carcinoma. Indian J Med Res 2017;146:S30-7. [PMID: 29578192 DOI: 10.4103/ijmr.IJMR_1812_15] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
34 Kang MK, Park JG, Lee HJ. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article. Medicine (Baltimore). 2018;97:e0611. [PMID: 29703062 DOI: 10.1097/md.0000000000010611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Begini P, Gigante E, Antonelli G, Carbonetti F, Iannicelli E, Anania G, Imperatrice B, Maria Pellicelli A, Delle Fave G, Marignani M. Sarcopenia Predicts Reduced Survival in Patients with Hepatocellular Carcinoma at First Diagnosis. Annals of Hepatology 2017;16:107-14. [DOI: 10.5604/16652681.1226821] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
36 Song J, Chen W, Zhu X, Zhao Z, Chen M, Huang L, Tu J, Zhou H, Zhou L, Ji J. Short-term efficacy, safety, and cost-effectiveness of transarterial chemoembolization with drug-eluting beads versus synchronous radiochemotherapy for cervical cancer. Int J Gynaecol Obstet 2019;147:29-35. [PMID: 31206641 DOI: 10.1002/ijgo.12888] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Jin YJ, Nah SY, Lee JW, Lee JI, Jeong S, Lee DH, Kim YS, Cho SG, Jeon YS. Utility of adding Primovist magnetic resonance imaging to analysis of hepatocellular carcinoma by liver dynamic computed tomography. Clin Gastroenterol Hepatol 2013;11:187-92. [PMID: 23142203 DOI: 10.1016/j.cgh.2012.11.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
38 Qiu F, Qiu F, Liu L, Liu J, Xu J, Huang X. The Role of Dermcidin in the Diagnosis and Staging of Hepatocellular Carcinoma. Genet Test Mol Biomarkers 2018;22:218-23. [PMID: 29641283 DOI: 10.1089/gtmb.2017.0230] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
39 Yoon JH, Choi JI, Jeong YY, Schenk A, Chen L, Laue H, Kim SY, Lee JM. Pre-treatment estimation of future remnant liver function using gadoxetic acid MRI in patients with HCC. J Hepatol. 2016;65:1155-1162. [PMID: 27476767 DOI: 10.1016/j.jhep.2016.07.024] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
40 Scherber PR, Gäbelein G, Eisele RM, Igna D, Glanemann M. [Early stage liver cancer : Hepatocellular carcinoma]. Chirurg 2018;89:281-8. [PMID: 29075797 DOI: 10.1007/s00104-017-0538-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Xu W, Rao Q, An Y, Li M, Xu G, Sang X, Lu X, Zhang Z, Mao Y. Proposal for subclassification to select patients for hepatectomy with intermediate hepatocellular carcinoma and Child-Pugh A liver function: A double-center study from China. Medicine (Baltimore). 2018;97:e11800. [PMID: 30095644 DOI: 10.1097/md.0000000000011800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Ladenheim MR, Kim NG, Nguyen P, Le A, Stefanick ML, Garcia G, Nguyen MH. Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study. BMJ Open Gastroenterol 2016;3:e000107. [PMID: 27493763 DOI: 10.1136/bmjgast-2016-000107] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
43 Ren F, Zhang J, Gao Z, Zhu H, Chen X, Liu W, Xue Z, Gao W, Wu R, Lv Y, Hu L. Racial disparities in the survival time of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma between Chinese patients and patients of other racial groups: A population-based study from 2004 to 2013. Oncol Lett 2018;16:7102-16. [PMID: 30546445 DOI: 10.3892/ol.2018.9550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 Jun L, Zhenlin Y, Renyan G, Yizhou W, Xuying W, Feng X, Yong X, Kui W, Jian L, Dong W, Hongyang W, Lehua S, Mengchao W, Feng S. Independent factors and predictive score for extrahepatic metastasis of hepatocellular carcinoma following curative hepatectomy. Oncologist 2012;17:963-9. [PMID: 22653882 DOI: 10.1634/theoncologist.2011-0447] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
45 Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011;18:228-40. [PMID: 21980250 DOI: 10.3747/co.v18i5.952] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
46 Bridges JF, Joy SM, Blauvelt BM, Yan W, Marsteller JA. An international comparison of stakeholder motivation to implement liver cancer control. Health Policy Plan 2015;30:645-55. [PMID: 24974105 DOI: 10.1093/heapol/czu044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
47 Galun DA, Bulajic P, Zuvela M, Basaric D, Ille T, Milicevic MN. Is there any benefit from expanding the criteria for the resection of hepatocellular carcinoma in cirrhotic liver? Experience from a developing country. World J Surg. 2012;36:1657-1665. [PMID: 22395347 DOI: 10.1007/s00268-012-1544-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
48 Wang Z, Teng D, Li Y, Hu Z, Liu L, Zheng H. A six-gene-based prognostic signature for hepatocellular carcinoma overall survival prediction. Life Sci 2018;203:83-91. [PMID: 29678742 DOI: 10.1016/j.lfs.2018.04.025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
49 Bolondi L. State of the art: hepatocellular carcinoma. Future Oncology 2014;10:1-6. [DOI: 10.2217/fon.14.215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
50 Lee SB, Kim KM, An J, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS. Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int. 2016;36:1351-1361. [PMID: 26913702 DOI: 10.1111/liv.13099] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
51 Guarino M, Tortora R, de Stefano G, Coppola C, Morisco F, Salomone Megna A, Izzo F, Nardone G, Piai G, Adinolfi LE. Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. J Gastroenterol Hepatol. 2018;33:1123-1130. [PMID: 28994145 DOI: 10.1111/jgh.14013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
52 Tomimaru Y, Takada K, Shirakawa T, Noguchi K, Morita S, Imamura H, Iwazawa T, Dono K. Surgical Apgar score for predicting complications after hepatectomy for hepatocellular carcinoma. Journal of Surgical Research 2018;222:108-14. [DOI: 10.1016/j.jss.2017.10.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
53 Pinter M, Ulbrich G, Sieghart W, Kölblinger C, Reiberger T, Li S, Ferlitsch A, Müller C, Lammer J, Peck-Radosavljevic M. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. Radiology 2015;277:903-12. [PMID: 26131911 DOI: 10.1148/radiol.2015142140] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
54 D'Souza JC, Sultan LR, Hunt SJ, Gade TP, Karmacharya MB, Schultz SM, Brice AK, Wood AKW, Sehgal CM. Microbubble-enhanced ultrasound for the antivascular treatment and monitoring of hepatocellular carcinoma. Nanotheranostics 2019;3:331-41. [PMID: 31687321 DOI: 10.7150/ntno.39514] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
55 Lee S, Kim BK, Song K, Park JY, Ahn SH, Kim SU, Han KH, Kim DY; Korea Central Cancer Registry. Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database. J Gastroenterol Hepatol. 2016;31:842-847. [PMID: 26513311 DOI: 10.1111/jgh.13218] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
56 Oweira H, Petrausch U, Helbling D, Schmidt J, Mehrabi A, Schöb O, Giryes A, Abdel-Rahman O. Prognostic value of site-specific extra-hepatic disease in hepatocellular carcinoma: a SEER database analysis. Expert Rev Gastroenterol Hepatol 2017;11:695-701. [PMID: 28276812 DOI: 10.1080/17474124.2017.1294485] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
57 Wang F, Jing X, Wang T, Li G, Li T, Zhang Q, Huang Y, Li J, Wang Y, Gao Y. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm. Am J Clin Pathol. 2012;137:937-945. [PMID: 22586053 DOI: 10.1309/ajcp0kzz5dsigmny] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
58 Gong J, Li R, Chen Y, Zhuo Z, Chen S, Cao J, Zhang Q, Chong Y, Hu B. HCC subtypes based on the activity changes of immunologic and hallmark gene sets in tumor and nontumor tissues. Brief Bioinform 2021:bbaa427. [PMID: 33515024 DOI: 10.1093/bib/bbaa427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Ei S, Hibi T, Tanabe M, Itano O, Shinoda M, Kitago M, Abe Y, Yagi H, Okabayashi K, Sugiyama D, Wakabayashi G, Kitagawa Y. Cryoablation provides superior local control of primary hepatocellular carcinomas of >2 cm compared with radiofrequency ablation and microwave coagulation therapy: an underestimated tool in the toolbox. Ann Surg Oncol. 2015;22:1294-1300. [PMID: 25287439 DOI: 10.1245/s10434-014-4114-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
60 Pan J, Wang F, Ye L. Doxorubicin-induced epithelial–mesenchymal transition through SEMA 4A in hepatocellular carcinoma. Biochemical and Biophysical Research Communications 2016;479:610-4. [DOI: 10.1016/j.bbrc.2016.09.167] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
61 Sun T, Ren Y, Kan X, Chen L, Zhang W, Yang F, Zheng C. Advanced Hepatocellular Carcinoma With Hepatic Arterioportal Shunts: Combination Treatment of Transarterial Chemoembolization With Apatinib. Front Mol Biosci 2020;7:607520. [PMID: 33344507 DOI: 10.3389/fmolb.2020.607520] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Liu C, Xiao GQ, Yan LN, Li B, Jiang L, Wen TF, Wang WT, Xu MQ, Yang JY. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol 2013; 19(11): 1811-1819 [PMID: 23555170 DOI: 10.3748/wjg.v19.i11.1811] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 68] [Article Influence: 8.4] [Reference Citation Analysis]
63 Cao W, Li J, Hu C, Shen J, Liu X, Xu Y, Ye Z. Symptom clusters and symptom interference of HCC patients undergoing TACE: a cross-sectional study in China. Support Care Cancer 2013;21:475-83. [DOI: 10.1007/s00520-012-1541-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
64 Park HC, Seong J, Tanaka M, Zeng ZC, Lim HY, Guan S, Bae SH, Tak WY. Multidisciplinary management of nonresectable hepatocellular carcinoma. Oncology 2011;81 Suppl 1:134-40. [PMID: 22212947 DOI: 10.1159/000333276] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
65 Morise Z, Kawabe N, Tomishige H, Nagata H, Kawase J, Arakawa S, Yoshida R, Isetani M. Recent advances in liver resection for hepatocellular carcinoma. Front Surg. 2014;1:21. [PMID: 25593945 DOI: 10.3389/fsurg.2014.00021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
66 Wang Y, Attar BM, Hinami K, Fuentes HE, Jaiswal P, Zhang H, Simons-Linares CS, Tafur AJ. Characteristics and Impacts of Venous Thromboembolism in Patients with Hepatocellular Carcinoma. J Gastrointest Cancer 2018;49:275-82. [PMID: 28374272 DOI: 10.1007/s12029-017-9945-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
67 Cucchetti A, Djulbegovic B, Tsalatsanis A, Vitale A, Hozo I, Piscaglia F, Cescon M, Ercolani G, Tuci F, Cillo U. When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology. 2015;61:905-914. [PMID: 25048515 DOI: 10.1002/hep.27321] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 8.3] [Reference Citation Analysis]
68 Xiao S, Hu Z, He Y, Jin H, Yang Y, Chen L, Chen Q, Luo Q, Liu J. Enhancement Effect of Microbubble-Enhanced Ultrasound in Microwave Ablation in Rabbit VX2 Liver Tumors. Biomed Res Int 2020;2020:3050148. [PMID: 32090074 DOI: 10.1155/2020/3050148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 Muaddi H, Sapisochin G. ASO Author Reflections: Salvage Liver Transplant for Recurrent Hepatocellular Carcinoma After Treatments With Curative Intent. Ann Surg Oncol 2018;25:794-5. [DOI: 10.1245/s10434-018-6960-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Yu SJ, Lee JH, Chung GE, Lee CH, Cho EJ, Jang ES, Kwak MS, Kim YJ, Yoon JH, Jang JJ, Lee HS. Validation of P2/MS for reflecting hepatic fibrosis in patients with hepatocellular carcinoma. Korean J Hepatol 2010;16:389-96. [PMID: 21415583 DOI: 10.3350/kjhep.2010.16.4.389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
71 Iavarone M, Colombo M. HBV-related HCC, clinical issues and therapy. Dig Liver Dis. 2011;43 Suppl 1:S32-S39. [PMID: 21195370 DOI: 10.1016/S1590-8658(10)60690-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
72 Lucatelli P, De Rubeis G, Ginnani Corradini L, Basilico F, Di Martino M, Lai Q, Ginanni Corradini S, Cannavale A, Nardis PG, Corona M, Saba L, Catalano C, Bezzi M. Intra-procedural dual phase cone beam computed tomography has a better diagnostic accuracy over pre-procedural MRI and MDCT in detection and characterization of HCC in cirrhotic patients undergoing TACE procedure. Eur J Radiol 2020;124:108806. [PMID: 31945673 DOI: 10.1016/j.ejrad.2019.108806] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
73 Agarwal S, Mullikin D, Scheurer ME, Smith V, Naik-Mathuria B, Guillerman RP, Foster JH, Diaz R, Sartain SE. Role of anticoagulation in the management of tumor thrombus: A 10-year single-center experience. Pediatr Blood Cancer 2021;68:e29173. [PMID: 34061441 DOI: 10.1002/pbc.29173] [Reference Citation Analysis]
74 Nishikawa H, Osaki Y. Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. Hepatol Res. 2014;44:149-158. [PMID: 23819582 DOI: 10.1111/hepr.12194] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
75 Kim YI, Park HC, Lim DH, Park HJ, Kang SW, Park SY, Kim JS, Han Y, Paik SW. Changes of the liver volume and the Child-Pugh score after high dose hypofractionated radiotherapy in patients with small hepatocellular carcinoma. Radiat Oncol J 2012;30:189-96. [PMID: 23346538 DOI: 10.3857/roj.2012.30.4.189] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
76 Im S, Jang ES, Lee JH, Lee CS, Kim BH, Chung JW, Kim JW, Jeong SH. Surveillance Rate and its Impact on Survival of Hepatocellular Carcinoma Patients in South Korea: A Cohort Study. Cancer Res Treat 2019;51:1357-69. [PMID: 30744319 DOI: 10.4143/crt.2018.430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
77 Wu L, Swan P, McCall J, Gane E, Holden A, Merrilees S, Munn S, Johnston P, Bartlett A. Intention-to-treat analysis of liver transplantation, resection and thermal ablation for hepatocellular carcinoma in a single centre. HPB (Oxford) 2018;20:966-76. [PMID: 29843986 DOI: 10.1016/j.hpb.2018.04.006] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
78 Li Y, Zheng Y, Zhao W, Liu B, Hu B, He X, Huang J, Lu L. Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma. Med Oncol 2013;30. [DOI: 10.1007/s12032-013-0730-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
79 Goh V, Sarker D, Osmany S, Cook GJ. Functional imaging techniques in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:1070-1079. [PMID: 22434049 DOI: 10.1007/s00259-012-2096-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
80 Walther Z, Jain D. Molecular pathology of hepatic neoplasms: classification and clinical significance. Patholog Res Int. 2011;2011:403929. [PMID: 21559202 DOI: 10.4061/2011/403929] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
81 Wilson GC, Geller DA. Evolving Surgical Options for Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2019;28:645-61. [DOI: 10.1016/j.soc.2019.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Galun D, Bogdanovic A, Djokic Kovac J, Bulajic P, Loncar Z, Zuvela M. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative-intent surgery for hepatocellular carcinoma: experience from a developing country. Cancer Manag Res. 2018;10:977-988. [PMID: 29765248 DOI: 10.2147/cmar.s161398] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
83 Perini MV, Starkey G, Fink MA, Bhandari R, Muralidharan V, Jones R, Christophi C. From minimal to maximal surgery in the treatment of hepatocarcinoma: A review. World J Hepatol 2015; 7(1): 93-100 [PMID: 25625000 DOI: 10.4254/wjh.v7.i1.93] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
84 Bertani S, Pineau P, Loli S, Moura J, Zimic M, Deharo E, Ruiz E. An atypical age-specific pattern of hepatocellular carcinoma in Peru: a threat for Andean populations. PLoS One 2013;8:e67756. [PMID: 23840771 DOI: 10.1371/journal.pone.0067756] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
85 Song Y, Cao L. N-myc downstream-regulated gene 1: Diverse and complicated functions in human hepatocellular carcinoma (Review). Oncol Lett 2013;6:1539-42. [PMID: 24260043 DOI: 10.3892/ol.2013.1636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
86 Lim DH, Lee H, Park HC, Lee JA, Kim SW, Yoo BC, Koh KC, Lee JH, Choi MS, Gwak GY. The efficacy of high-dose 3-dimensional conformal radiation therapy in patients with small hepatocellular carcinoma not eligible for other local modalities. Am J Clin Oncol. 2013;36:162-166. [PMID: 22391433 DOI: 10.1097/coc.0b013e3182438dae] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
87 Shen Y, Hsu C, Cheng A. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2010;45:794-807. [DOI: 10.1007/s00535-010-0270-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 3.9] [Reference Citation Analysis]
88 Kim SU, Park JH, Kim HS, Lee JM, Lee HG, Kim H, Choi SH, Baek S, Kim BK, Park JY. Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma. Yonsei Med J. 2015;56:1296-1306. [PMID: 26256972 DOI: 10.3349/ymj.2015.56.5.1296] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
89 Lin H, Jiao X, Yu B, Du J, Xu H, Dong A, Wan C. Clinical significance of serum 14-3-3 beta in patients with hepatocellular carcinoma. CBM 2017;20:143-50. [DOI: 10.3233/cbm-160533] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
90 Titano J, Noor A, Kim E. Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages. Semin Intervent Radiol 2017;34:109-15. [PMID: 28579678 DOI: 10.1055/s-0037-1602709] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
91 Erstad DJ, Tanabe KK. Hepatocellular carcinoma: early-stage management challenges. J Hepatocell Carcinoma 2017;4:81-92. [PMID: 28721349 DOI: 10.2147/JHC.S107370] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
92 Jung SM, Jang JW, You CR, Yoo SH, Kwon JH, Bae SH, Choi JY, Yoon SK, Chung KW, Kay CS, Jung HS. Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases. J Gastroenterol Hepatol. 2012;27:684-689. [PMID: 21916984 DOI: 10.1111/j.1440-1746.2011.06917.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
93 Levi DM, Nishida S. Liver Transplantation for Hepatocellular Carcinoma: Lessons Learned and Future Directions. Clinics in Liver Disease 2011;15:717-25. [DOI: 10.1016/j.cld.2011.08.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
94 Werner KT, Perez ST. Role of Nurse Practitioners in the Management of Cirrhotic Patients. The Journal for Nurse Practitioners 2012;8:816-21. [DOI: 10.1016/j.nurpra.2012.08.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
95 Li B, Huang P, Qiu J, Liao Y, Hong J, Yuan Y. MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosis. Med Oncol. 2014;31:230. [PMID: 25218269 DOI: 10.1007/s12032-014-0230-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
96 Uygun Ilikhan S, Bilici M, Sahin H, Demir Akca AS, Can M, Oz II, Guven B, Buyukuysal MC, Ustundag Y. Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma. World J Gastroenterol 2015; 21(22): 6999-7007 [PMID: 26078578 DOI: 10.3748/wjg.v21.i22.6999] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
97 Zhao Q, Zhu K, Yue J, Qi Z, Jiang S, Xu X, Feng R, Wang R. Comparison of intra-arterial chemoembolization with and without radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a meta-analysis. Ther Clin Risk Manag 2017;13:21-31. [PMID: 28053537 DOI: 10.2147/TCRM.S126181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
98 Lee JS, Chon YE, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kang W, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Kim HY, Kim TH, Yoo K, Ha Y, Kim MN, Lee JH, Hwang SG, Kim SS, Cho HJ, Cheong JY, Cho SW, Park SH, Heo NY, Hong YM, Yoon KT, Cho M, Park JG, Kang MK, Park SY, Kweon YO, Tak WY, Jang SY, Sinn DH, Kim SU; Korean TACE Study Group. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. Yonsei Med J 2021;62:12-20. [PMID: 33381930 DOI: 10.3349/ymj.2021.62.1.12] [Reference Citation Analysis]
99 Stefansdottir J, Christensen E, Schiødt FV. Hepatocellular carcinoma in Danish patients: a single Copenhagen center experience. Scandinavian Journal of Gastroenterology 2017;52:768-72. [DOI: 10.1080/00365521.2017.1304985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
100 Liang YR, Guo Z, Jiang JH, Xiang BD, Li LQ. Thymosin α1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study. Oncol Lett 2016;12:3513-8. [PMID: 27900029 DOI: 10.3892/ol.2016.5121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
101 Somma F, D'Angelo R, Serra N, Gatta G, Grassi R, Fiore F. Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)? PLoS One 2015;10:e0129573. [PMID: 26110810 DOI: 10.1371/journal.pone.0129573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
102 Roderburg C, Gautheron J, Luedde T. TNF-Dependent Signaling Pathways in Liver Cancer: Promising Targets for Therapeutic Strategies? Dig Dis 2012;30:500-7. [DOI: 10.1159/000341700] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
103 Heng-jun G, Yao-jun Z, Min-shan C, Mei-xian C, Jun-ting H, Li X, Lau WY. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma. Liver Int 2014;34:612-20. [DOI: 10.1111/liv.12307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
104 Wang ZF, Hu R, Pang JM, Zhang GZ, Yan W, Li ZN. Serum long noncoding RNA LRB1 as a potential biomarker for predicting the diagnosis and prognosis of human hepatocellular carcinoma. Oncol Lett. 2018;16:1593-1601. [PMID: 30008842 DOI: 10.3892/ol.2018.8825] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
105 Zhou Y, Liang C, Xue F, Chen W, Zhi X, Feng X, Bai X, Liang T. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation. Oncotarget 2015;6:10350-65. [PMID: 25871400 DOI: 10.18632/oncotarget.3585] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 11.2] [Reference Citation Analysis]
106 Kim SS, Cho HJ, Nam JS, Kim HJ, Kang DR, Won JH, Kim J, Kim JK, Lee JH, Kim BH, Lee MY, Cho SW, Cheong JY. Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. J Korean Med Sci 2018;33:e6. [PMID: 29215815 DOI: 10.3346/jkms.2018.33.e6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
107 Yi PS, Zhang M, Zhao JT, Xu MQ. Liver resection for intermediate hepatocellular carcinoma. World J Hepatol 2016; 8(14): 607-615 [PMID: 27190577 DOI: 10.4254/wjh.v8.i14.607] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
108 Chen J, Fang A, Chen M, Tuoheti Y, Zhou Z, Xu L, Chen J, Pan Y, Wang J, Zhu H, Zhang Y. A novel inflammation-based nomogram system to predict survival of patients with hepatocellular carcinoma. Cancer Med 2018;7:5027-35. [PMID: 30259688 DOI: 10.1002/cam4.1787] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
109 Xing M, Kokabi N, Prajapati HJ, Close O, Ludwig JM, Kim HS. Survival in unresectable AJCC stage I and II HCC and the effect of DEB-TACE: SEER versus tertiary cancer center cohort study. J Comp Eff Res. 2016;5:141-154. [PMID: 26946950 DOI: 10.2217/cer.15.54] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
110 Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol. 2013;13:60. [PMID: 23566041 DOI: 10.1186/1471-230x-13-60] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 9.4] [Reference Citation Analysis]
111 Chan KM, Wu TH, Cheng CH, Lee CF, Wu TJ, Chou HS, Lee WC. Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan. Cancer Manag Res 2019;11:1013-21. [PMID: 30774429 DOI: 10.2147/CMAR.S186678] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
112 Kamran AU, Liu Y, Li FE, Liu S, Wu JL, Zhang YW. Transcatheter Arterial Chemoembolization With Gelatin Sponge Microparticles Treated for BCLC Stage B Hepatocellular Carcinoma: A Single Center Retrospective Study. Medicine (Baltimore) 2015;94:e2154. [PMID: 26717358 DOI: 10.1097/MD.0000000000002154] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
113 Kalva SP, Pectasides M, Yeddula K, Ganguli S, Blaszkowsky LS, Zhu AX. Factors Affecting Survival following Chemoembolization with Doxorubicin-eluting Microspheres for Inoperable Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2013;24:257-65. [DOI: 10.1016/j.jvir.2012.10.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
114 Wong TC, Chiang CL, Lee AS, Lee VH, Yeung CS, Ho CH, Cheung TT, Ng KK, Chok SH, Chan AC, Dai WC, Wong FC, Luk MY, Leung TW, Lo CM. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. Surg Oncol. 2019;28:228-235. [PMID: 30851906 DOI: 10.1016/j.suronc.2019.01.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
115 Hassan A, Tsuda Y, Asai A, Yokohama K, Nakamura K, Sujishi T, Ohama H, Tsuchimoto Y, Fukunishi S, Abdelaal UM, Arafa UA, Hassan AT, Kassem AM, Higuchi K. Effects of Oral L-Carnitine on Liver Functions after Transarterial Chemoembolization in Intermediate-Stage HCC Patients. Mediators Inflamm 2015;2015:608216. [PMID: 26664151 DOI: 10.1155/2015/608216] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
116 Messaoudi R, Jaziri F, Mtibaa A, Grand-Brochier M, Ali HM, Amouri A, Fourati H, Chabrot P, Gargouri F, Vacavant A. Ontology-Based Approach for Liver Cancer Diagnosis and Treatment. J Digit Imaging 2019;32:116-30. [PMID: 30066122 DOI: 10.1007/s10278-018-0115-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
117 Yan SY, Zhang Y, Sun C, Cao HX, Li GM, Wang YQ, Fan JG. The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinoma. Oncol Lett 2016;12:951-5. [PMID: 27446375 DOI: 10.3892/ol.2016.4694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
118 Ribeiro de Souza A, Reig M, Bruix J. Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opinion on Pharmacotherapy 2016;17:1923-36. [DOI: 10.1080/14656566.2016.1225722] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
119 Murawa D, Polom K, Rho YS, Murawa P. Developments in near-infrared-guided hepatobiliary, pancreatic and other upper gastrointestinal surgery: NIR guided surgery in HB, pancreatic and UGI tract. Contrast Media Mol Imaging 2013;8:211-9. [DOI: 10.1002/cmmi.1519] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
120 Huang J, Zhang Y, Peng Z, Gao H, Xu L, Jiao LR, Chen M. A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy. J Cancer Res Clin Oncol. 2013;139:1709-1719. [PMID: 23982274 DOI: 10.1007/s00432-013-1497-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
121 Goh GB, Li JW, Chang PE, Chow KY, Tan CK. Deciphering the epidemiology of hepatocellular carcinoma through the passage of time: A study of 1,401 patients across 3 decades. Hepatol Commun 2017;1:564-71. [PMID: 29404479 DOI: 10.1002/hep4.1059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
122 Takahashi M, Maruyama H, Shimada T, Kamezaki H, Okabe S, Kanai F, Yoshikawa M, Yokosuka O. Linear enhancement after radio-frequency ablation for hepatocellular carcinoma: is it a sign of recurrence? Ultrasound Med Biol 2012;38:1902-10. [PMID: 23026230 DOI: 10.1016/j.ultrasmedbio.2012.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
123 Minici R, Ammendola M, Manti F, Siciliano MA, Giglio E, Minici M, Melina M, Currò G, Laganà D. Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization as a Bridging Therapy in Patients with Early Stage Hepatocellular Carcinoma and Child-Pugh Stage B Eligible for Liver Transplant. Front Pharmacol 2021;12:634084. [PMID: 33897421 DOI: 10.3389/fphar.2021.634084] [Reference Citation Analysis]
124 Liu X, Hou Y, Wang X, Yu L, Wang X, Jiang L, Yang Z. Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer. Hepatol Int 2020;14:567-76. [DOI: 10.1007/s12072-020-10046-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
125 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2017;6:387-396. [PMID: 29312973 DOI: 10.21037/hbsn.2017.11.01] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
126 Jun CH, Yoon JH, Cho E, Shin SS, Cho SB, Kim HJ, Park CH, Kim HS, Choi SK, Rew JS. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment. Medicine (Baltimore) 2017;96:e6745. [PMID: 28445298 DOI: 10.1097/MD.0000000000006745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
127 Manini MA, Sangiovanni A, Martinetti L, Viganò D, La Mura V, Aghemo A, Iavarone M, Crespi S, Nicolini A, Colombo M. Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma. Liver Transpl. 2015;21:1259-1269. [PMID: 26074360 DOI: 10.1002/lt.24196] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
128 Lee YB, Lee DH, Cho Y, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim HC, Yi NJ, Lee KW. Comparison of transarterial chemoembolization and hepatic resection for large solitary hepatocellular carcinoma: a propensity score analysis. J Vasc Interv Radiol. 2015;26:651-659. [PMID: 25824316 DOI: 10.1016/j.jvir.2015.02.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
129 Rong G, Wang H, Bowlus CL, Wang C, Lu Y, Zeng Z, Qu J, Lou M, Chen Y, An L. Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48:132-141. [PMID: 25762349 DOI: 10.1007/s12016-015-8483-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
130 Li J, Wei H, Liu Y, Li Q, Guo H, Guo Y, Chang Z. Curcumin Inhibits Hepatocellular Carcinoma via Regulating miR-21/TIMP3 Axis. Evid Based Complement Alternat Med 2020;2020:2892917. [PMID: 32724322 DOI: 10.1155/2020/2892917] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
131 Muaddi H, Al-Adra DP, Beecroft R, Ghanekar A, Moulton CA, Doyle A, Selzner M, Wei A, McGilvray ID, Gallinger S, Grant DR, Cattral MS, Greig PD, Kachura J, Cleary SP, Sapisochin G. Liver Transplantation is Equally Effective as a Salvage Therapy for Patients with Hepatocellular Carcinoma Recurrence Following Radiofrequency Ablation or Liver Resection with Curative Intent. Ann Surg Oncol. 2018;25:991-999. [PMID: 29327179 DOI: 10.1245/s10434-017-6329-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
132 Abdalla M, Khairy E, Louka ML, Ali-Labib R, Ibrahim EA. Vitamin D receptor gene methylation in hepatocellular carcinoma. Gene 2018;653:65-71. [PMID: 29432829 DOI: 10.1016/j.gene.2018.02.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
133 Lee J, Yoon WS, Koom WS, Rim CH. Role of local treatment including radiotherapy in Barcelona Clinic of Liver Cancer stage C patients: a nationwide cohort analysis in South Korea. Cancer Manag Res 2019;11:1373-82. [PMID: 30809102 DOI: 10.2147/CMAR.S193761] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
134 Jin GZ, Li Y, Cong WM, Yu H, Dong H, Shu H, Liu XH, Yan GQ, Zhang L, Zhang Y. iTRAQ-2DLC-ESI-MS/MS based identification of a new set of immunohistochemical biomarkers for classification of dysplastic nodules and small hepatocellular carcinoma. J Proteome Res. 2011;10:3418-3428. [PMID: 21631109 DOI: 10.1021/pr200482t] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 4.7] [Reference Citation Analysis]
135 Bargellini I, Florio F, Golfieri R, Grosso M, Lauretti DL, Cioni R. Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology. Cardiovasc Intervent Radiol. 2014;37:438-444. [PMID: 23719667 DOI: 10.1007/s00270-013-0656-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
136 Lin YM, Taiji R, Calandri M, Odisio BC. Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy. Curr Oncol Rep 2021;23:67. [PMID: 33855606 DOI: 10.1007/s11912-021-01056-4] [Reference Citation Analysis]
137 Cauble S, Abbas A, Balart L, Bazzano L, Medvedev S, Shores N. United States women receive more curative treatment for hepatocellular carcinoma than men. Dig Dis Sci. 2013;58:2817-2825. [PMID: 23812858 DOI: 10.1007/s10620-013-2731-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
138 Shaker MK, Abdel Fattah HI, Sabbour GS, Montasser IF, Abdelhakam SM, El Hadidy E, Yousry R, El Dorry AK. Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients. World J Hepatol 2017; 9(9): 469-476 [PMID: 28396717 DOI: 10.4254/wjh.v9.i9.469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
139 Deshpande R, O'Reilly D, Sherlock D. Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. Int J Hepatol 2011;2011:686074. [PMID: 21994867 DOI: 10.4061/2011/686074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
140 Xia F, Lau WY, Xu Y, Wu L, Qian C, Bie P. Does hepatic ischemia-reperfusion injury induced by hepatic pedicle clamping affect survival after partial hepatectomy for hepatocellular carcinoma? World J Surg. 2013;37:192-201. [PMID: 22965538 DOI: 10.1007/s00268-012-1781-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
141 Mohkam K, Dorez D, Mabrut J. Liver transplantation from donors after circulatory death following the withdrawal of life-sustaining therapies: An answer to the shortage of grafts? Journal of Visceral Surgery 2016;153:325-6. [DOI: 10.1016/j.jviscsurg.2016.05.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
142 Kokabi N, Duszak R, Xing M, Howard DH, Applegate KE, Camacho JC, Kim HS. Cancer-directed therapy and potential impact on survivals in nonresected hepatocellular carcinoma: SEER-Medicare population study. Future Oncology 2017;13:2021-33. [DOI: 10.2217/fon-2017-0116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
143 Kalafateli M, Triantos C, Tsochatzis E, Michalaki M, Koutroumpakis E, Thomopoulos K, Kyriazopoulou V, Jelastopulu E, Burroughs A, Lambropoulou-Karatza C, Nikolopoulou V. Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis. World J Gastroenterol 2015; 21(10): 3020-3029 [PMID: 25780301 DOI: 10.3748/wjg.v21.i10.3020] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
144 Norman GL, Gatselis NK, Shums Z, Liaskos C, Bogdanos DP, Koukoulis GK, Dalekos GN. Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. World J Hepatol 2015; 7(14): 1875-1883 [PMID: 26207169 DOI: 10.4254/wjh.v7.i14.1875] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
145 Cauchy F, Fuks D, Belghiti J. HCC: current surgical treatment concepts. Langenbecks Arch Surg 2012;397:681-95. [DOI: 10.1007/s00423-012-0911-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
146 Znati S, Carter R, Vasquez M, Westhorpe A, Shahbakhti H, Prince J, Vlckova P, De Vellis C, Bascal Z, Loizidou M, Sharma RA. Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib. Cancers (Basel) 2020;12:E1878. [PMID: 32668592 DOI: 10.3390/cancers12071878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
147 Meischl T, Rasoul-Rockenschaub S, Györi G, Sieghart W, Reiberger T, Trauner M, Soliman T, Berlakovich G, Pinter M. C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation. PLoS One 2019;14:e0216677. [PMID: 31141535 DOI: 10.1371/journal.pone.0216677] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
148 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187-1195. [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 110] [Article Influence: 19.7] [Reference Citation Analysis]
149 Baek CK, Choi JY, Kim KA, Park MS, Lim JS, Chung YE, Kim MJ, Kim KW. Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT. Clin Radiol. 2012;67:148-156. [PMID: 21920517 DOI: 10.1016/j.crad.2011.08.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
150 Milgrom DP, Maluccio MA, Koniaris LG. Management of Hepatocellular Carcinoma (HCC). Curr Surg Rep 2016;4. [DOI: 10.1007/s40137-016-0143-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
151 Ammendola M, Sacco R, Sammarco G, Piardi T, Zuccalà V, Patruno R, Zullo A, Zizzo N, Nardo B, Marech I, Crovace A, Gadaleta CD, Pessaux P, Ranieri G. Mast cells positive to tryptase, endothelial cells positive to protease-activated receptor-2, and microvascular density correlate among themselves in hepatocellular carcinoma patients who have undergone surgery. Onco Targets Ther 2016;9:4465-71. [PMID: 27499640 DOI: 10.2147/OTT.S105368] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
152 Liu PH, Hsu CY, Lee YH, Su CW, Hsia CY, Huang YH, Chiou YY, Lin HC, Huo TI. Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology. Medicine (Baltimore) 2015;94:e1772. [PMID: 26469917 DOI: 10.1097/MD.0000000000001772] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
153 Chen J, Lai L, Lin Q, Huang W, Cai M, Zhu K, Huang M. Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study. Oncotarget 2017;8:408-17. [PMID: 27880724 DOI: 10.18632/oncotarget.13427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
154 Sellers CM, Uhlig J, Ludwig JM, Taddei T, Stein SM, Lim JK, Kim HS. The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance. Cancer Med 2019;8:5948-58. [PMID: 31436905 DOI: 10.1002/cam4.2251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
155 Ertle J, Dechêne A, Sowa J, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn W, Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis: Absence of Cirrhosis in NASH-Derived HCC. Int J Cancer 2011;128:2436-43. [DOI: 10.1002/ijc.25797] [Cited by in Crossref: 290] [Cited by in F6Publishing: 279] [Article Influence: 29.0] [Reference Citation Analysis]
156 Li SQ, Huang T, Shen SL, Hua YP, Hu WJ, Kuang M, Peng BG, Liang LJ. Anatomical versus non-anatomical liver resection for hepatocellular carcinoma exceeding Milan criteria. Br J Surg 2017;104:118-27. [PMID: 27696379 DOI: 10.1002/bjs.10311] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
157 Yeh ML, Huang CF, Huang CI, Hsieh MY, Hou NJ, Lin IH, Liang PC, Tsai YS, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, Yu ML, Chuang WL. The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. Kaohsiung J Med Sci 2019;35:624-32. [PMID: 31254328 DOI: 10.1002/kjm2.12105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
158 Kim H, Chung JW, Choi SH, Im S, Yamasaki Y, Jun S, Jae HJ, Park JH. Augmentation of Chemotherapeutic Infusion Effect by TSU-68, an Oral Targeted Antiangiogenic Agent, in a Rabbit VX2 Liver Tumor Model. Cardiovasc Intervent Radiol 2012;35:168-75. [DOI: 10.1007/s00270-010-0081-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
159 Park C, Kim JH, Kim PH, Kim SY, Gwon DI, Chu HH, Park M, Hur J, Kim JY, Kim DJ. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Korean J Radiol 2021;22:213-24. [PMID: 32901464 DOI: 10.3348/kjr.2020.0325] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
160 Lucatelli P, De Rubeis G, Rocco B, Basilico F, Cannavale A, Abbatecola A, Nardis PG, Corona M, Brozzetti S, Catalano C, Bezzi M. Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study. BMC Gastroenterol 2021;21:51. [PMID: 33535972 DOI: 10.1186/s12876-021-01631-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
161 Kasai Y, Hatano E, Seo S, Taura K, Yasuchika K, Okajima H, Kaido T, Uemoto S. Proposal of selection criteria for operative resection of hepatocellular carcinoma with inferior vena cava tumor thrombus incorporating hepatic arterial infusion chemotherapy. Surgery. 2017;162:742-751. [PMID: 28705491 DOI: 10.1016/j.surg.2017.05.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
162 Forner A, Rodríguez-Lopez C, Reig M. Natural history and staging for hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2012;1:183-5. [PMID: 31186883 DOI: 10.1002/cld.129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
163 Vaca-Paniagua F, Oliver J, Nogueira da Costa A, Merle P, McKay J, Herceg Z, Holmila R. Targeted deep DNA methylation analysis of circulating cell-free DNA in plasma using massively parallel semiconductor sequencing. Epigenomics 2015;7:353-62. [PMID: 26077425 DOI: 10.2217/epi.14.94] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
164 Zhao Y, Fang Z, Luo J, Liu Q, Xu G, Pan H, Wei W, Yan Z. Evaluation of extrahepatic collateral arteries in hepatocellular carcinoma in three independent groups in a single center. Exp Ther Med 2015;10:2366-74. [PMID: 26668643 DOI: 10.3892/etm.2015.2822] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
165 Bera R, Chiou C, Yu M, Peng J, He C, Hsu C, Huang H, Ho UY, Lin S, Lin Y, Hsieh S. Functional genomics identified a novel protein tyrosine phosphatase receptor type f-mediated growth inhibition in hepatocarcinogenesis: BERA, CHIOU, ET AL. Hepatology 2014;59:2238-50. [DOI: 10.1002/hep.27030] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
166 Suh CH, Kim KW, Park SH, Kim SY, Woo D, Shin S, Pyo J, Shinagare AB, Ramaiya NH, Lim Y. Performing Gadoxetic Acid–Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. American Journal of Roentgenology 2018;210:W63-9. [DOI: 10.2214/ajr.17.18300] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
167 Poon RT, Cheung TT, Kwok PC, Lee AS, Li TW, Loke KL, Chan SL, Cheung MT, Lai TW, Cheung CC. Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer. 2015;4:51-69. [PMID: 26020029 DOI: 10.1159/000367728] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
168 李鹏, 陈玉涵, 张世斌, 丁惠国. 乙型肝炎肝硬化患者不同肝癌筛查方案的比较及对预后影响. 世界华人消化杂志 2015; 23(20): 3298-3303 [DOI: 10.11569/wcjd.v23.i20.3298] [Reference Citation Analysis]
169 Venkat R, Hannallah JR, Krouse RS, Maegawa FB. Preoperative thrombocytopenia and outcomes of hepatectomy for hepatocellular carcinoma. Journal of Surgical Research 2016;201:498-505. [DOI: 10.1016/j.jss.2015.08.038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
170 Jung YK, Jung CH, Seo YS, Kim JH, Kim TH, Yoo YJ, Kang SH, Yim SY, Suh SJ, An H, Yim HJ, Yeon JE, Byun KS, Um SH. BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. J Gastroenterol Hepatol 2016;31:467-74. [PMID: 26332049 DOI: 10.1111/jgh.13152] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
171 Chen Q, Ayer T, Chhatwal J. Optimal M -Switch Surveillance Policies for Liver Cancer in a Hepatitis C–Infected Population. Operations Research 2018;66:673-96. [DOI: 10.1287/opre.2017.1706] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
172 Wang Z, Fan Q, Wang M, Wang E, Li H, Liu L. Comparison between Child-Pugh Score and albumin-bilirubin grade in patients treated with the combination therapy of transarterial chemoembolization and sorafenib for hepatocellular carcinoma. Ann Transl Med 2020;8:537. [PMID: 32411760 DOI: 10.21037/atm.2020.02.114] [Reference Citation Analysis]
173 Kim MN, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, Kim DY. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scand J Gastroenterol 2019;54:1283-90. [PMID: 31593481 DOI: 10.1080/00365521.2019.1673478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
174 Zhu K, Chen J, Lai L, Meng X, Zhou B, Huang W, Cai M, Shan H. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study. Radiology. 2014;272:284-293. [PMID: 24708192 DOI: 10.1148/radiol.14131946] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 10.7] [Reference Citation Analysis]
175 Chen CS, Li FK, Guo CY, Xiao JC, Hu HT, Cheng HT, Zheng L, Zong DW, Ma JL, Jiang L, Li HL. Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Oncotarget 2016;7:7241-52. [PMID: 26769845 DOI: 10.18632/oncotarget.6892] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
176 Dasse KD, Lander MJ, Novelli PM. Chemoembolization With Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma. J Adv Pract Oncol 2016;7:764-78. [PMID: 29670812 DOI: 10.6004/jadpro.2016.7.7.8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
177 Min YW, Gwak GY, Lee MW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Clinical course of sub-centimeter-sized nodules detected during surveillance for hepatocellular carcinoma. World J Gastroenterol 2012; 18(21): 2654-2660 [PMID: 22690074 DOI: 10.3748/wjg.v18.i21.2654] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
178 Wang G, Liu Y, Zhou SF, Qiu P, Xu L, Wen P, Wen J, Xiao X. Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. Hepatol Int. 2016;10:501-510. [PMID: 26856326 DOI: 10.1007/s12072-015-9700-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
179 Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39:328-348. [PMID: 29846945 DOI: 10.1002/med.21515] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 12.0] [Reference Citation Analysis]
180 Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology. 2011;81 Suppl 1:158-164. [PMID: 22212951 DOI: 10.1159/000333280] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 7.5] [Reference Citation Analysis]
181 Kim HY, Park JW, Nam BH, Kim HK, Choi JI, Kim TH, Kim HB, Kim CM. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. J Gastroenterol Hepatol. 2011;26:1612-1618. [PMID: 21517968 DOI: 10.1111/j.1440-1746.2011.06751.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
182 Lee SW, Lee TY, Peng YC, Yang SS, Yeh HZ, Chang CS. The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma. J Dig Dis 2020;21:287-92. [PMID: 32315498 DOI: 10.1111/1751-2980.12866] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
183 Yu T, Ye X, Wen Z, Zhu G, Su H, Han C, Huang K, Qin W, Liao X, Yang C, Liu Z, Wang X, Xu B, Su M, Lv Z, Lau WY, Peng T. Intraoperative Indocyanine Green Retention Test of Left Hemiliver in Decision-Making for Patients With Hepatocellular Carcinoma Undergoing Right Hepatectomy. Front Surg 2021;8:709017. [PMID: 34604294 DOI: 10.3389/fsurg.2021.709017] [Reference Citation Analysis]
184 Bauschke A, Altendorf-Hofmann A, Freesmeyer M, Winkens T, Malessa C, Schierz JH, Teichgraeber U, Settmacher U. [Selective internal radioembolization in nonresectable hepatocellular carcinoma]. Chirurg 2016;87:956-63. [PMID: 27460230 DOI: 10.1007/s00104-016-0259-1] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
185 Liu F, Luo L, Wei Y, Wang W, Wen T, Yang J, Xu M, Li B. Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population. Oncotarget 2017;8:16488-97. [PMID: 28147320 DOI: 10.18632/oncotarget.14870] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
186 Chen L, Yu CX, Zhong BY, Zhu HD, Jin ZC, Zhu GY, Zhang Q, Ni CF, Teng GJ. Development of TACE Refractoriness Scores in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:615133. [PMID: 33981722 DOI: 10.3389/fmolb.2021.615133] [Reference Citation Analysis]
187 Kwon JH, Lee N, Park JY, Yu YS, Kim JP, Shin JH, Kim DS, Joh JW, Kim DS, Choi KY, Kang KJ, Kim G, Moon YH, Wang HJ. Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma. PLoS One 2013;8:e64260. [PMID: 23785399 DOI: 10.1371/journal.pone.0064260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
188 Park HK, Lee SS, Im CB, Im C, Cha RR, Kim WS, Cho HC, Lee JM, Kim HJ, Kim TH, Jung WT, Lee OJ. Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma. BMC Cancer 2019;19:822. [PMID: 31429755 DOI: 10.1186/s12885-019-6040-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
189 Sayan M, Yegya-Raman N, Greco SH, Gui B, Zhang A, Chundury A, Grandhi MS, Hochster HS, Kennedy TJ, Langan RC, Malhotra U, Rustgi VK, Shah MM, Spencer KR, Carpizo DR, Nosher JL, Jabbour SK. Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes. Front Oncol 2019;9:345. [PMID: 31275846 DOI: 10.3389/fonc.2019.00345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
190 Fuks D, Dokmak S, Paradis V, Diouf M, Durand F, Belghiti J. Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: An intention-to-treat analysis. Hepatology. 2012;55:132-140. [PMID: 21932387 DOI: 10.1002/hep.24680] [Cited by in Crossref: 173] [Cited by in F6Publishing: 168] [Article Influence: 19.2] [Reference Citation Analysis]
191 Lee HL, Tsai JT, Chen CY, Lin YC, Ho CB, Ting LL, Kuo CC, Lai IC, Lin CY, Tang JH, Huang YM, Kao WY, Cheng SW, Shen CN, Chen SW, Chiou JF. Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization. Ther Adv Med Oncol 2019;11:1758835919889002. [PMID: 31839809 DOI: 10.1177/1758835919889002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Hetta HF, Mekky MA, Zahran AM, Abdel-Malek MO, Ramadan HK, Shafik EA, Abbas WA, Abbas El-Masry M, Mohamed NA, Kamel AA, Marraiki N, Beshbishy AM, Batiha GE, Osman HA, Koneru G, El-Mokhtar MA. Regulatory B Cells and Their Cytokine Profile in HCV-Related Hepatocellular Carcinoma: Association with Regulatory T Cells and Disease Progression. Vaccines (Basel) 2020;8:E380. [PMID: 32664587 DOI: 10.3390/vaccines8030380] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
193 Nemes B, Gelley F, Piros L, Zádori G, Görög D, Fehérvári I, Kóbori L, Sárváry E, Nagy P, Kiss A, Doros A. The impact of Milan criteria on liver transplantation for hepatocellular carcinoma: first 15 years' experience of the Hungarian Liver Transplant Program. Transplant Proc 2011;43:1272-4. [PMID: 21620108 DOI: 10.1016/j.transproceed.2011.03.077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
194 Mecci AJ, Kemos P, Leen C, Lawson A, Richardson P, Khakoo SI, Agarwal K, Mutimer D, Rosenberg WM, Foster GR, Irving WL; HCV Research UK. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. Aliment Pharmacol Ther 2019;50:204-14. [PMID: 31149748 DOI: 10.1111/apt.15296] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
195 Yi Y, Ni XC, Liu G, Yin YR, Huang JL, Gan W, Zhou PY, Guan RY, Zhou C, Sun BY, Qiu SJ. Clinical significance of herpes virus entry mediator expression in hepatitis B virus-related hepatocellular carcinoma. Oncol Lett 2020;20:19. [PMID: 32774492 DOI: 10.3892/ol.2020.11880] [Reference Citation Analysis]
196 Hyun MH, Chung SM. Randomized, controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma: HEPATOLOGY, Vol. XX, No. X, 2015. Hepatology 2015;62:980-980. [DOI: 10.1002/hep.27714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
197 Mohkam K, Golse N, Bonal M, Ledochowski S, Rode A, Selmaji IE, Merle P, Ducerf C, Mornex F, Mabrut J. Conformal radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma: is it safe? Future Oncology 2016;12:1577-86. [DOI: 10.2217/fon-2016-0083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
198 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
199 Khalaf MH, Shah RP, Green V, Vezeridis AM, Liang T, Kothary N. Comparison of Opioid Medication Use after Conventional Chemoembolization versus Drug-Eluting Embolic Chemoembolization. J Vasc Interv Radiol 2020;31:1292-9. [PMID: 32654960 DOI: 10.1016/j.jvir.2020.04.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
200 Shi J, Keller JM, Zhang J, Keller ET. A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors. J Hepatocell Carcinoma 2014;1:1-7. [PMID: 27508171 DOI: 10.2147/JHC.S44537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
201 Taddei TH. A multidisciplinary approach: group dynamics. J Clin Gastroenterol 2013;47 Suppl:S27-9. [PMID: 23632364 DOI: 10.1097/MCG.0b013e31829331de] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
202 Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V, Dimitriadis G. Pathways and targets in hepatocellular carcinoma. Expert Review of Anticancer Therapy 2014;12:1347-57. [DOI: 10.1586/era.12.113] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
203 Zhong JH, Pan LH, Wang YY, Cucchetti A, Yang T, You XM, Ma L, Gong WF, Xiang BD, Peng NF, Wu FX, Li LQ. Optimizing stage of single large hepatocellular carcinoma: A study with subgroup analysis by tumor diameter. Medicine (Baltimore) 2017;96:e6608. [PMID: 28403105 DOI: 10.1097/MD.0000000000006608] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
204 Qin LF, Qin JM, Zhang JQ, Lv XP, Huang LY, Wang JJ. CXCL12 and CXCR4 polymorphisms and expressions in peripheral blood from patients of hepatocellular carcinoma. Future Oncol. 2018;14:1261-1271. [PMID: 29741398 DOI: 10.2217/fon-2017-0613] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
205 Zhang Y, Fan W, Wang Y, Lu L, Fu S, Yang J, Huang Y, Yao W, Li J. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis. Oncologist. 2015;20:1417-1424. [PMID: 26446238 DOI: 10.1634/theoncologist.2015-0196] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 7.2] [Reference Citation Analysis]
206 Cui W, Fan W, Zhang Q, Wen J, Huang Y, Yang J, Li J, Wang Y. Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin. Oncotarget 2017;8:79165-74. [PMID: 29108296 DOI: 10.18632/oncotarget.16298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
207 Chung BM, Park HJ, Park SB, Lee JB, Ahn HS, Kim YS. Differentiation of small arterial enhancing hepatocellular carcinoma from non-tumorous arterioportal shunt with an emphasis on the precontrast CT scan. Abdom Imaging 2015;40:2200-9. [DOI: 10.1007/s00261-015-0439-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
208 Song YG, Shin SW, Cho SK, Choi D, Rhim H, Lee MW, Kim YS, Park KB, Park HS, Choo SW, Do YS, Choo IW, Hyun D. Transarterial chemoembolization as first-line therapy for hepatocellular carcinomas infeasible for ultrasound-guided radiofrequency ablation: a retrospective cohort study of 116 patients. Acta Radiol 2015;56:70-7. [PMID: 24518688 DOI: 10.1177/0284185114520857] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
209 Zhang G, Li R, Zhao X, Meng S, Ye J, Zhao L. Validation of the American Joint Committee on Cancer eighth edition staging system in patients undergoing hepatectomy for hepatocellular carcinoma: a US population-based study. J Surg Res 2018;222:55-68. [PMID: 29273376 DOI: 10.1016/j.jss.2017.09.044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
210 Marqueen KE, Kim E, Ang C, Mazumdar M, Buckstein M, Ferket BS. Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma. JCO Oncol Pract 2021;17:e266-77. [PMID: 33417490 DOI: 10.1200/OP.20.00443] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
211 Nomair AM, Madkour MA, Shamseya MM, Elsheredy HG, Shokr A. Profiling of plasma metabolomics in patients with hepatitis C-related liver cirrhosis and hepatocellular carcinoma. Clin Exp Hepatol 2019;5:317-26. [PMID: 31893244 DOI: 10.5114/ceh.2019.89478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
212 Feng LH, Dong H, Lau WY, Yu H, Zhu YY, Zhao Y, Lin YX, Chen J, Wu MC, Cong WM. Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2017;143:293-303. [PMID: 27743138 DOI: 10.1007/s00432-016-2286-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
213 Kan X, Liang B, Zhou G, Xiong B, Pan F, Ren Y, Cao Y, Wang J, Yang F, Zheng C. Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front Oncol 2020;10:970. [PMID: 32733791 DOI: 10.3389/fonc.2020.00970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
214 Koduru P, Suzuki R, Lakhtakia S, Ramchandani M, Makmun D, Bhutani MS. Role of endoscopic ultrasound in diagnosis and management of hepatocellular carcinoma.J Hepatocell Carcinoma. 2015;2:143-149. [PMID: 27508203 DOI: 10.2147/JHC.S60868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
215 Cheng S, Yang J, Shen F, Zhou W, Wang Y, Cong W, Yang GS, Cheng H, Hu H, Gao C, Guo J, Li A, Meng Y, Jiang X, Yang Y, Qian G, Luo M, Hu B, Man X, Zhang B, Su C, Zhou F, Li N, Shi J, Wang M, Zheng Y, Guo W, Sun J, Wang H, Lau WY, Wu MC. Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement. Oncotarget 2016;7:40816-29. [PMID: 27027235 DOI: 10.18632/oncotarget.8386] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
216 Hong J, Yuan YF, Wang JP, Liao Y, Zou RH, Zhu CL, Li BK, Liang Y, Huang PZ, Wang ZW, Lin WY, Zeng YX, Dai JL, Chung RT. Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma. Cancer Res. 2014;74:1845-56. [PMID: 24477596 DOI: 10.1158/0008-5472.can-13-2104] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 3.9] [Reference Citation Analysis]
217 Loi M, Comito T, Franzese C, Dominici L, Lo Faro L, Clerici E, Franceschini D, Mancosu P, Reggiori G, Gallo P, Badalamenti M, Scorsetti M. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity. J Cancer Res Clin Oncol 2021;147:927-36. [PMID: 32945972 DOI: 10.1007/s00432-020-03389-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
218 Zhang Y, Qu S, Yi W, Zhai J, Zhang X, Wei L, Lau WY, Wu M, Shen F, Fan H, Wu D. A Pretreatment CT Model Predicts Survival Following Chemolipiodolization in Patients With Hepatocellular Carcinoma. Technol Cancer Res Treat 2019;18:1533033819844488. [PMID: 31204599 DOI: 10.1177/1533033819844488] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
219 Sieghart W, Pinter M, Hucke F, Graziadei I, Schöniger-Hekele M, Müller C, Vogel W, Trauner M, Peck-Radosavljevic M. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology 2013;57:2224-34. [PMID: 22961713 DOI: 10.1002/hep.26057] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 7.6] [Reference Citation Analysis]
220 Toyoda H, Hiraoka A, Tada T, Michitaka K, Takaguchi K, Tsuji K, Itobayashi E, Takizawa D, Hirooka M, Koizumi Y, Ochi H, Joko K, Kisaka Y, Shimizu Y, Tajiri K, Tani J, Taniguchi T, Toshimori A, Fujioka S, Kumada T. Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis. Ther Apher Dial 2017;21:465-72. [PMID: 28880488 DOI: 10.1111/1744-9987.12563] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
221 Yamashita R, Long J, Saleem A, Rubin DL, Shen J. Deep learning predicts postsurgical recurrence of hepatocellular carcinoma from digital histopathologic images. Sci Rep 2021;11:2047. [PMID: 33479370 DOI: 10.1038/s41598-021-81506-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
222 Nomair AM, Issa NM, Madkour MA, Shamseya MM. The clinical significance of serum miRNA-224 expression in hepatocellular carcinoma. Clin Exp Hepatol 2020;6:20-7. [PMID: 32166120 DOI: 10.5114/ceh.2020.93052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
223 Wang Y, Attar BM, Fuentes HE, Yu J, Zhang H, Tafur AJ. Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients With Hepatocellular Carcinoma. Clin Appl Thromb Hemost 2018;24:471-6. [PMID: 28288526 DOI: 10.1177/1076029617699088] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
224 Arai K, Fukumoto T, Tanaka M, Kuramitsu K, Kido M, Kinoshita H, Matsumoto T, Toyama H, Asari S, Goto T, Ajiki T, Ku Y. Pathological complete response after percutaneous isolated hepatic perfusion in hepatocellular carcinoma with portal vein tumor thrombosis: a case report. Surg Case Rep 2016;2:50. [PMID: 27230652 DOI: 10.1186/s40792-016-0178-x] [Reference Citation Analysis]
225 Jung SW, Park NH, Shin JW, Park BR, Kim CJ, Lee JE, Shin ES, Kim JA, Chung YH. Polymorphisms of DNA repair genes in Korean hepatocellular carcinoma patients with chronic hepatitis B: possible implications on survival. J Hepatol. 2012;57:621-627. [PMID: 22659345 DOI: 10.1016/j.jhep.2012.04.039] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
226 Guarino M, Stroffolini T, Lombardo FL, Loperto I, Auriemma F, Gentile I, Caporaso N, Morisco F. Lack of evidence that adherence to standard of care therapy improves survival in subjects with hepatocellular carcinoma in clinical practice. J Med Virol 2015;87:1368-76. [PMID: 25802203 DOI: 10.1002/jmv.24187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
227 Gao J, Zhen R, Liao H, Zhuang W, Guo W. Pharmacokinetics of continuous transarterial infusion of 5-fluorouracil in patients with advanced hepatocellular carcinoma. Oncol Lett. 2018;15:7175-7181. [PMID: 29725440 DOI: 10.3892/ol.2018.8242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
228 White JA, Redden DT, Bryant MK, Dorn D, Saddekni S, Abdel Aal AK, Zarzour J, Bolus D, Smith JK, Gray S, Eckhoff DE, DuBay DA. Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. HPB (Oxford) 2014;16:1095-101. [PMID: 25158123 DOI: 10.1111/hpb.12313] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
229 Naganuma A, Hoshino T, Ohno N, Ogawa Y, Murakami T, Horiguchi S, Uehara D, Suzuki Y, Hatanaka T, Kudo T, Ishihara H, Sato K, Kakizaki S, Takagi H. β-Hydroxy-β-methyl Butyrate/L-Arginine/L-Glutamine Supplementation for Preventing Hand-Foot Skin Reaction in Sorafenib for Advanced Hepatocellular Carcinoma. In Vivo 2019;33:155-61. [PMID: 30587616 DOI: 10.21873/invivo.11452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
230 Feng D, Wang M, Hu J, Li S, Zhao S, Li H, Liu L. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. Ann Transl Med 2020;8:553. [PMID: 32411776 DOI: 10.21037/atm.2020.02.116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
231 Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-radosavljevic M, Sieghart W. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. Journal of Hepatology 2014;61:1287-96. [DOI: 10.1016/j.jhep.2014.07.002] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 11.4] [Reference Citation Analysis]
232 Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol 2015; 21(12): 3462-3471 [PMID: 25834310 DOI: 10.3748/wjg.v21.i12.3462] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 51] [Article Influence: 8.5] [Reference Citation Analysis]
233 Zhang EL, Liang BY, Chen XP, Huang ZY. Severity of liver cirrhosis: a key role in the selection of surgical modality for Child-Pugh A hepatocellular carcinoma. World J Surg Oncol. 2015;13:148. [PMID: 25879526 DOI: 10.1186/s12957-015-0567-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
234 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022. [PMID: 21374666 DOI: 10.1002/hep.24199.] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
235 Miura JT, Johnston FM, Tsai S, Eastwood D, Banerjee A, Christians KK, Turaga KK, Gamblin TC. Surgical resection versus ablation for hepatocellular carcinoma ≤ 3 cm: a population-based analysis. HPB (Oxford) 2015;17:896-901. [PMID: 26228076 DOI: 10.1111/hpb.12446] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
236 Zhu J, Yin T, Xu Y, Lu XJ. Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. J Cell Physiol. 2019;234:12122-12132. [PMID: 30644100 DOI: 10.1002/jcp.28048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
237 Chen L, Sun T, Chen S, Ren Y, Yang F, Zheng C. The efficacy of surgery in advanced hepatocellular carcinoma: a cohort study. World J Surg Oncol 2020;18:119. [PMID: 32487104 DOI: 10.1186/s12957-020-01887-8] [Reference Citation Analysis]
238 Qadan M, Kothary N, Sangro B, Palta M. The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Am Soc Clin Oncol Educ Book 2020;40:1-8. [PMID: 32213090 DOI: 10.1200/EDBK_280811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
239 Yang T, Lau WY, Zhang H, Huang B, Lu JH, Wu MC. Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: Surgeons’ perspective. World J Gastroenterol 2015; 21(27): 8256-8261 [PMID: 26217077 DOI: 10.3748/wjg.v21.i27.8256] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
240 Baek MY, Yoo JJ, Jeong SW, Jang JY, Kim YK, Jeong SO, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim YJ, Park SY. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization. Korean J Intern Med 2019;34:1223-32. [PMID: 30360019 DOI: 10.3904/kjim.2018.058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
241 Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, Xie GS, Li LQ. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260:329-340. [PMID: 24096763 DOI: 10.1097/sla.0000000000000236] [Cited by in Crossref: 215] [Cited by in F6Publishing: 144] [Article Influence: 35.8] [Reference Citation Analysis]
242 Cheung TT, Wong TC, Chan SC. Technical note on ALPPS for a patient with advanced hepatocellular carcinoma associated with invasion of the inferior vena cava. Hepatobiliary Pancreat Dis Int 2016;15:319-23. [PMID: 27298110 DOI: 10.1016/s1499-3872(15)60414-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
243 Ahmadzadehfar H, Habibi E, Ezziddin S, Wilhelm K, Fimmers R, Spengler U, Palmedo H, Strunk H, Schild HH, Biersack HJ, Risse J. Survival after 131I-labeled lipiodol therapy for hepatocellular carcinoma: A single-center study based on a long-term follow-up. Nuklearmedizin 2018;53:46-53. [DOI: 10.3413/nukmed-0610-13-07] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
244 Wu J, Song L, Zhao DY, Guo B, Liu J. Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2014; 20(31): 10960-10968 [PMID: 25152600 DOI: 10.3748/wjg.v20.i31.10960] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
245 Lee WC, Lee CF, Cheng CH, Wu TJ, Chou HS, Wu TH, Soong RS, Chan KM, Yu MC, Chen MF. Outcomes of liver resection for hepatocellular carcinoma in liver transplantation era. Eur J Surg Oncol. 2015;41:1144-1152. [PMID: 26163047 DOI: 10.1016/j.ejso.2015.05.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
246 Tian M, Zhang X, Huang G, Fan W, Li J, Zhang Y. Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization. Abdom Radiol (NY) 2019;44:3304-11. [PMID: 31250181 DOI: 10.1007/s00261-019-02116-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
247 Zhao Y, Cai G, Zhou L, Liu L, Qi X, Bai M, Li Y, Fan D, Han G. Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review. Asia Pac J Clin Oncol. 2013;9:357-364. [PMID: 23714021 DOI: 10.1111/ajco.12081] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
248 Campagnolo L, Telesca C, Massimiani M, Stuhlmann H, Angelico M, Lenci I, Manzia TM, Tariciotti L, Lehmann G, Baiocchi L. Different expression of VEGF and EGFL7 in human hepatocellular carcinoma. Dig Liver Dis 2016;48:76-80. [PMID: 26542361 DOI: 10.1016/j.dld.2015.09.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
249 Wang E, Xia D, Bai W, Yuan J, Li X, Niu J, Yin Z, Xia J, Cai H, Fan D, Han G, Liu L. Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma. BMC Cancer 2019;19:409. [PMID: 31039750 DOI: 10.1186/s12885-019-5570-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
250 Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J Hepatol. 2014;60:118-126. [PMID: 24012941 DOI: 10.1016/j.jhep.2013.08.022] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 8.9] [Reference Citation Analysis]
251 Wang W, Gu D, Wei J, Ding Y, Yang L, Zhu K, Luo R, Rao SX, Tian J, Zeng M. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI. Eur Radiol. 2020;30:3004-3014. [PMID: 32002645 DOI: 10.1007/s00330-019-06585-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
252 Saab S, Jackson C, Nieto J, Francois F. Hepatitis C in African Americans. Am J Gastroenterol 2014;109:1576-84; quiz 1575, 1585. [PMID: 25178700 DOI: 10.1038/ajg.2014.243] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
253 Proneth A, Zeman F, Schlitt HJ, Schnitzbauer AA. Is Resection or Transplantation the ideal Treatment in Patients with Hepatocellular Carcinoma in Cirrhosis if Both Are Possible? A Systematic Review and Metaanalysis. Ann Surg Oncol 2014;21:3096-107. [DOI: 10.1245/s10434-014-3808-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
254 Xu WW, Li B, Lai ET, Chen L, Huang JJ, Cheung AL, Cheung PC. Water extract from Pleurotus pulmonarius with antioxidant activity exerts in vivo chemoprophylaxis and chemosensitization for liver cancer. Nutr Cancer 2014;66:989-98. [PMID: 25072857 DOI: 10.1080/01635581.2014.936950] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
255 Cipriani F, Fantini C, Ratti F, Lauro R, Tranchart H, Halls M, Scuderi V, Barkhatov L, Edwin B, Troisi RI, Dagher I, Reggiani P, Belli G, Aldrighetti L, Abu Hilal M. Laparoscopic liver resections for hepatocellular carcinoma. Can we extend the surgical indication in cirrhotic patients? Surg Endosc. 2018;32:617-626. [PMID: 28717870 DOI: 10.1007/s00464-017-5711-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
256 Sun H, Ni J, Jiang X, Chen D, Chen Y, Xu L. The effect of lipiodol deposition in HCC after TACE on the necrosis range of PMCT. Onco Targets Ther 2017;10:3835-42. [PMID: 28814882 DOI: 10.2147/OTT.S137312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
257 Kim SS, Nam JS, Cho HJ, Won JH, Kim JW, Ji JH, Yang MJ, Park JH, Noh CK, Shin SJ, Lee KM, Cho SW, Cheong JY. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2017;32:199-207. [PMID: 27194671 DOI: 10.1111/jgh.13448] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
258 Chen F, Wang F, Sun S, Zhu M, Liu Z. Size measurements of hepatocellular carcinoma: comparisons between contrast and two-dimensional ultrasound. BMC Gastroenterol 2020;20:390. [PMID: 33213375 DOI: 10.1186/s12876-020-01535-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Parente DB, Perez RM, Eiras-Araujo A, Oliveira Neto JA, Marchiori E, Constantino CP, Amorim VB, Rodrigues RS. MR imaging of hypervascular lesions in the cirrhotic liver: a diagnostic dilemma. Radiographics. 2012;32:767-787. [PMID: 22582358 DOI: 10.1148/rg.323115131] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
260 Mohkam K, Farges O, Pruvot F, Muscari F, Régimbeau J, Regenet N, Sa Cunha A, Dokmak S, Mabrut J. Toward a standard technique for laparoscopic distal pancreatectomy? Synthesis of the 2013 ACHBT Spring workshop. Journal of Visceral Surgery 2015;152:167-78. [DOI: 10.1016/j.jviscsurg.2015.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
261 Yan X, Fu X, Cai C, Zi X, Yao H, Qiu Y. Validation of models in patients with hepatocellular carcinoma: comparison of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging system in a Chinese cohort. European Journal of Gastroenterology & Hepatology 2015;27:1180-6. [DOI: 10.1097/meg.0000000000000418] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
262 Cho JY, Paik YH, Park HC, Yu JI, Sohn W, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. Liver Int. 2014;34:795-801. [PMID: 24350564 DOI: 10.1111/liv.12445] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
263 Hou YF, Li B, Wei YG, Yang JY, Wen TF, Xu MQ, Yan LV, Chen KF. Second Hepatectomy Improves Survival in Patients With Microvascular Invasive Hepatocellular Carcinoma Meeting the Milan Criteria. Medicine (Baltimore) 2015;94:e2070. [PMID: 26632890 DOI: 10.1097/MD.0000000000002070] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
264 Li G, Cai G, Li D, Yin W. MicroRNAs and liver disease: viral hepatitis, liver fibrosis and hepatocellular carcinoma. Postgrad Med J 2014;90:106-12. [PMID: 24243965 DOI: 10.1136/postgradmedj-2013-131883] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
265 Chen Z, Zhao H, Qiao X, Yi C, Gao S, Gao W, Liu Z. Effect of Microbubble-Enhanced Ultrasound on Radiofrequency Ablation of Rabbit Liver. Ultrasound Med Biol 2018;44:1451-9. [PMID: 29685588 DOI: 10.1016/j.ultrasmedbio.2018.03.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
266 Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. [PMID: 27785449 DOI: 10.2147/jhc.s61146] [Cited by in Crossref: 418] [Cited by in F6Publishing: 253] [Article Influence: 83.6] [Reference Citation Analysis]
267 Pan Z, Zhuang J, Ji C, Cai Z, Liao W, Huang Z. Curcumin inhibits hepatocellular carcinoma growth by targeting VEGF expression. Oncol Lett 2018;15:4821-6. [PMID: 29552121 DOI: 10.3892/ol.2018.7988] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
268 Timaran Montenegro DE, Torres Ramirez CA, Mateo C YS, Govea Palma J, Quiñones JC, Orozco Vazquez JS. CT-Based Hepatic Residual Volume and Predictors of Outcomes of Patients with Hepatocellular Carcinoma Unsuitable for Surgical Therapy Undergoing Transarterial Chemoembolization. Acad Radiol 2020;27:807-14. [PMID: 31575476 DOI: 10.1016/j.acra.2019.09.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
269 Zhang Y, Fan W, Zhu K, Lu L, Fu S, Huang J, Wang Y, Yang J, Huang Y, Yao W, Li J. Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response. Oncotarget 2015;6:24550-9. [PMID: 26093084 DOI: 10.18632/oncotarget.4076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
270 Ekmekcioglu O, Tabakci ON, Bozdag Kaplan N, Hasanefendioglu Bayrak A, Battal M. Factors affecting the response to treatment and survival in hepatocellular carcinoma patients treated with transarterial radioembolisation: a single-centre experience. Eur J Gastroenterol Hepatol 2021;33:926-31. [PMID: 33731592 DOI: 10.1097/MEG.0000000000002117] [Reference Citation Analysis]
271 Shi Y, Zhai B. A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma. Gastrointest Tumors 2016;3:90-102. [PMID: 27904861 DOI: 10.1159/000445888] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
272 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1686] [Article Influence: 321.3] [Reference Citation Analysis]
273 Wang J, Luo J, Yin X, Huang W, Cao H, Wang G, Wang J, Zhou J. Jiedu Granule Combined with Transcatheter Arterial Chemoembolization and Gamma Knife Radiosurgery in Treating Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Biomed Res Int 2019;2019:4696843. [PMID: 31341898 DOI: 10.1155/2019/4696843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
274 Zeng DW, Zhu YY, Huang Q, Zhang JM, Wu YL, Dong J, Jiang JJ, Liu YR. Hepatitis B surface antigen in late hepatitis B infection. J Med Virol. 2015;87:380-387. [PMID: 25604455 DOI: 10.1002/jmv.24078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
275 Liu S, Guo L, Li H, Zhang B, Sun J, Zhou C, Zhou J, Fan J, Ye Q. Postoperative Adjuvant Trans-Arterial Chemoembolization for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus. Ann Surg Oncol 2018;25:2098-104. [DOI: 10.1245/s10434-018-6438-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
276 Lee HJ, Yeon JE, Suh SJ, Lee SJ, Yoon EL, Kang K, Yoo YJ, Kim JH, Seo YS, Yim HJ. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver. 2014;8:177-185. [PMID: 24672660 DOI: 10.5009/gnl.2014.8.2.177] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
277 Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Kasuya K, Sano T, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis. Liver Cancer 2020;9:275-92. [PMID: 32647631 DOI: 10.1159/000505190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
278 Hu Z, Zhang Q, Zhou J, Li Z, Xiang J, Zhou L, Wu J, Zhang M, Zheng S. Impact of multiple liver resections prior to salvage liver transplantation on survival in patients with recurrent HCC. BMJ Open 2015;5:e008429. [PMID: 26353871 DOI: 10.1136/bmjopen-2015-008429] [Reference Citation Analysis]
279 Minocha J, Salem R, Lewandowski RJ. Transarterial chemoembolization and yittrium-90 for liver cancer and other lesions. Clin Liver Dis. 2014;18:877-890. [PMID: 25438288 DOI: 10.1016/j.cld.2014.07.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
280 Colombo M, Raoul J, Lencioni R, Galle PR, Zucman-rossi J, Bañares R, Seehofer D, Neuhaus P, Johnson P. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. European Journal of Gastroenterology & Hepatology 2013;25:639-51. [DOI: 10.1097/meg.0b013e32835e33bb] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
281 Harada N, Shirabe K, Maeda T, Kayashima H, Ishida T, Maehara Y. Blood Transfusion is Associated with Recurrence of Hepatocellular Carcinoma After Hepatectomy in Child–Pugh Class A Patients. World J Surg 2015;39:1044-51. [DOI: 10.1007/s00268-014-2891-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
282 Berumen J, Hemming A. Liver transplantation for hepatocellular carcinoma. Abdom Radiol 2018;43:185-92. [DOI: 10.1007/s00261-017-1217-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
283 Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel RS, Sata M. Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol 2013;6:511-9. [PMID: 24151531 DOI: 10.1593/tlo.13481] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
284 Yeh ML, Kuo HT, Huang CI, Huang CF, Hsieh MY, Liang PC, Lin IH, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, Yu ML, Chuang WL. Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. Kaohsiung J Med Sci 2021;37:145-53. [PMID: 33022892 DOI: 10.1002/kjm2.12303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
285 Sato Y, Nishiofuku H, Yasumoto T, Nakatsuka A, Matsuo K, Kodama Y, Okubo H, Abo D, Takaki H, Inaba Y, Yamakado K. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study. J Vasc Interv Radiol 2018;29:1061-7. [PMID: 29934260 DOI: 10.1016/j.jvir.2018.03.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
286 Holmila R, Sklias A, Muller DC, Degli Esposti D, Guilloreau P, Mckay J, Sangrajrang S, Srivatanakul P, Hainaut P, Merle P, Herceg Z, Nogueira da Costa A. Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma. PLoS One 2017;12:e0174265. [PMID: 28333958 DOI: 10.1371/journal.pone.0174265] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
287 Chun YH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Kim BK, Choi GH, Kim KS, Choi JS, Ahn SH. Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. Eur J Cancer. 2011;47:2568-2575. [PMID: 21835608 DOI: 10.1016/j.ejca.2011.07.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
288 Reiberger T, Chen Y, Ramjiawan RR, Hato T, Fan C, Samuel R, Roberge S, Huang P, Lauwers GY, Zhu AX. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Nat Protoc. 2015;10:1264-1274. [PMID: 26203823 DOI: 10.1038/nprot.2015.080] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 9.2] [Reference Citation Analysis]
289 Peisen F, Maurer M, Grosse U, Nikolaou K, Syha R, Ketelsen D, Artzner C, Bitzer M, Horger M, Grözinger G. Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE). Eur Radiol 2020;30:3782-92. [PMID: 32125515 DOI: 10.1007/s00330-020-06734-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
290 Qi X, Li J, Deng H, Li H, Su C, Guo X. Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Oncotarget. 2016;7:45283-45301. [PMID: 27304193 DOI: 10.18632/oncotarget.9942] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 17.7] [Reference Citation Analysis]
291 Belghiti J, Fuks D. Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer. 2012;1:71-82. [PMID: 24159575 DOI: 10.1159/000342403] [Cited by in Crossref: 54] [Cited by in F6Publishing: 64] [Article Influence: 7.7] [Reference Citation Analysis]
292 Gao F, Li X, Geng M, Ye X, Liu H, Liu Y, Wan G, Wang X. Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma. Medicine (Baltimore). 2015;94:e639. [PMID: 25789957 DOI: 10.1097/md.0000000000000639] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
293 Chow PK. Resection for hepatocellular carcinoma: is it justifiable to restrict this to the American Association for the Study of the Liver/Barcelona Clinic for Liver Cancer criteria? J Gastroenterol Hepatol. 2012;27:452-457. [PMID: 22142283 DOI: 10.1111/j.1440-1746.2011.07034.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
294 Fraum TJ, Tsai R, Rohe E, Ludwig DR, Salter A, Nalbantoglu I, Heiken JP, Fowler KJ. Differentiation of Hepatocellular Carcinoma from Other Hepatic Malignancies in Patients at Risk: Diagnostic Performance of the Liver Imaging Reporting and Data System Version 2014. Radiology 2018;286:158-72. [PMID: 28853673 DOI: 10.1148/radiol.2017170114] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 17.5] [Reference Citation Analysis]
295 Smirne C, Grossi G, Pinato DJ, Burlone ME, Mauri FA, Januszewski A, Oldani A, Minisini R, Sharma R, Pirisi M. Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma. Dig Liver Dis. 2015;47:488-494. [PMID: 25864774 DOI: 10.1016/j.dld.2015.03.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
296 Coletta D, De Padua C, Parrino C, De Peppo V, Oddi A, Frigieri C, Grazi GL. Laparoscopic Liver Surgery: What Are the Advantages in Patients with Cirrhosis and Portal Hypertension? Systematic Review and Meta-Analysis with Personal Experience. J Laparoendosc Adv Surg Tech A 2020;30:1054-65. [PMID: 32707003 DOI: 10.1089/lap.2020.0408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
297 Wiggermann P, Jung E, Stroszczynski C. Radiofrequenzablation – ist eine Technik am Ende? Radiologe 2012;52:9-14. [DOI: 10.1007/s00117-011-2206-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
298 Poulou LS, Botsa E, Thanou I, Ziakas PD, Thanos L. Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol 2015; 7(8): 1054-1063 [PMID: 26052394 DOI: 10.4254/wjh.v7.i8.1054] [Cited by in Crossref: 154] [Cited by in F6Publishing: 119] [Article Influence: 25.7] [Reference Citation Analysis]
299 He Z, Chen J, Wang J, Xu L, Zhou Z, Chen M, Zhang Y, Shi M. Expression of hepatitis B surface antigen in liver tissues can serve as a predictor of prognosis for hepatitis B virus-related hepatocellular carcinoma patients after liver resection. Eur J Gastroenterol Hepatol 2021;33:76-82. [PMID: 32049678 DOI: 10.1097/MEG.0000000000001698] [Reference Citation Analysis]
300 Hsiao WD, Peng CY, Chuang PH, Lai HC, Cheng KS, Chou JW, Chen YY, Yu CJ, Feng CL, Su WP, Chen SH, Kao JT. Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study. BMC Gastroenterol 2016;16:50. [PMID: 27117280 DOI: 10.1186/s12876-016-0464-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
301 Gavanier M, Ayav A, Sellal C, Orry X, Claudon M, Bronowicki J, Laurent V. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1. European Journal of Radiology 2016;85:103-12. [DOI: 10.1016/j.ejrad.2015.10.024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
302 Olthoff KM, Forner A, Hübscher S, Fung J. What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation? Liver Transpl. 2011;17 Suppl 2:S26-S33. [PMID: 21656653 DOI: 10.1002/lt.22352] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
303 Schütte K, Tippelt B, Schulz C, Röhl F, Feneberg A, Seidensticker R, Arend J, Malfertheiner P. Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). Clinical Nutrition 2015;34:1122-7. [DOI: 10.1016/j.clnu.2014.11.007] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 8.5] [Reference Citation Analysis]
304 Semaan S, Makkar J, Lewis S, Chatterji M, Kim E, Taouli B. Imaging of Hepatocellular Carcinoma Response After 90 Y Radioembolization. American Journal of Roentgenology 2017;209:W263-76. [DOI: 10.2214/ajr.17.17993] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
305 Jin R, Lin H, Li G, Xu J, Shi L, Chang C, Cai X. TR4 nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression. Cell Death Dis 2018;9:283. [PMID: 29449527 DOI: 10.1038/s41419-018-0287-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
306 Meyers D, Nixon NA, Franko A, Ng D, Tam VC. Tumour thrombus of the inferior vena cava extending into the right atrium in the setting of colon cancer. BMJ Case Rep 2017;2017:bcr2016218107. [PMID: 28193644 DOI: 10.1136/bcr-2016-218107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
307 Farid AA, Afify NA, Alsharnoby AA, Abdelsameea E, Bedair HM. Predictive Role of AURKA rs 1047972 Gene Polymorphism and the Risk of Development of Hepatocellular Carcinoma. Immunol Invest 2021;:1-11. [PMID: 34018460 DOI: 10.1080/08820139.2021.1920609] [Reference Citation Analysis]
308 Ciuleanu T, Bazin I, Lungulescu D, Miron L, Bondarenko I, Deptala A, Rodriguez-Torres M, Giantonio B, Fox NL, Wissel P, Egger J, Ding M, Kalyani RN, Humphreys R, Gribbin M, Sun W. A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. Ann Oncol. 2016;27:680-687. [PMID: 26802147 DOI: 10.1093/annonc/mdw004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
309 Rodríguez de Lope C, Reig ME, Darnell A, Forner A. Approach of the patient with a liver mass. Frontline Gastroenterol 2012;3:252-62. [PMID: 28839677 DOI: 10.1136/flgastro-2012-100146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
310 Bai M, Reynolds NR, Mccorkle R. The promise of clinical interventions for hepatocellular carcinoma from the west to mainland China. Pall Supp Care 2013;11:503-22. [DOI: 10.1017/s1478951512001137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
311 Sun H, Zhang M, Liu R, Liu Y, Hou Y, Wu C. Endovascular implantation of 125I seed combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. Future Oncol. 2018;14:1165-1176. [PMID: 29334777 DOI: 10.2217/fon-2017-0354] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
312 Abbasoglu O. Role of liver resection in the management of multinodular hepatocellular carcinoma. World J Hepatol 2015; 7(20): 2237-2240 [PMID: 26380648 DOI: 10.4254/wjh.v7.i20.2237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
313 Negm O, Abou Saif S, El Gharib M, Yousef M, Abd-Elsalam S. Role of low-molecular-weight heparins in prevention of thromboembolic complication after transarterial chemoembolization in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2017;29:317-21. [PMID: 27893491 DOI: 10.1097/MEG.0000000000000790] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
314 Chen S, Ji R, Shi X, Wang Z, Zhu D. Retrospective analysis of efficacy, safety, and prognostic factors in a cohort of Chinese hepatocellular carcinoma patients treated with drug-eluting bead transarterial chemoembolization. Braz J Med Biol Res 2019;52:e8467. [PMID: 31800729 DOI: 10.1590/1414-431X20198467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
315 Li L, Mo F, Hui EP, Chan SL, Koh J, Tang NLS, Yu SCH, Yeo W. The association of liver function and quality of life of patients with liver cancer. BMC Gastroenterol 2019;19:66. [PMID: 31046687 DOI: 10.1186/s12876-019-0984-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
316 Mansour MA, Khalifa MO. Antibiotic prophylaxis in transarterial chemoembolization of hepatocellular carcinoma. Arab J Gastroenterol 2018;19:16-20. [PMID: 29503075 DOI: 10.1016/j.ajg.2018.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
317 Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, Miladinovic B, Kumar A. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol 2013; 5(7): 364-371 [PMID: 23898369 DOI: 10.4254/wjh.v5.i7.364] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
318 Zhang JB, Chen Y, Zhang B, Xie X, Zhang L, Ge N, Ren Z, Ye SL. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2011;23:787-793. [PMID: 21730869 DOI: 10.1097/meg.0b013e32834902dd] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
319 Toyoda H, Kumada T, Tada T, Yama T, Mizuno K, Sone Y, Maeda A, Kaneoka Y, Akita T, Tanaka J. Differences in the impact of prognostic factors for hepatocellular carcinoma over time. Cancer Sci 2017;108:2438-44. [PMID: 28945309 DOI: 10.1111/cas.13406] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
320 Oh TK, Choi YR, Cho JY, Yoon YS, Han HS, Park IS, Ryu JH. The High-Sensitivity C-Reactive Protein/Albumin Ratio Predicts Long-Term Oncologic Outcomes after Curative Resection for Hepatocellular Carcinoma. J Clin Med 2018;7:E139. [PMID: 29880755 DOI: 10.3390/jcm7060139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
321 Sheng XR, Xing SG, Wang RD, Chen K, Jia WD. Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma. Onco Targets Ther 2018;11:909-17. [PMID: 29503566 DOI: 10.2147/OTT.S153381] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
322 Chen BB, Shih IL, Wu CH, Hsu C, Chen CH, Shih TT, Liu KL, Liang PC. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies. J Vasc Interv Radiol. 2014;25:371-378. [PMID: 24468045 DOI: 10.1016/j.jvir.2013.10.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
323 Yi PS, Wang H, Li JS. Evolution and current status of the subclassification of intermediate hepatocellular carcinoma. World J Gastrointest Surg 2020; 12(3): 85-92 [PMID: 32218891 DOI: 10.4240/wjgs.v12.i3.85] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
324 Doemel LA, Chapiro J, Laage Gaupp F, Savic LJ, Kucukkaya AS, Petukhova A, Tefera J, Zeevi T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. Eur Radiol 2021;31:2737-46. [PMID: 33123796 DOI: 10.1007/s00330-020-07381-9] [Reference Citation Analysis]
325 Luo C, Pu J, Liu F, Long X, Wang C, Wei H, Tang Q. MicroRNA-200c expression is decreased in hepatocellular carcinoma and associated with poor prognosis. Clin Res Hepatol Gastroenterol 2019;43:715-21. [PMID: 30962170 DOI: 10.1016/j.clinre.2019.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
326 Li BK, Huang PZ, Qiu JL, Liao YD, Hong J, Yuan YF. Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma. Diagn Pathol. 2014;9:226. [PMID: 25466449 DOI: 10.1186/s13000-014-0226-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
327 Ha Y, Shim JH, Kim SO, Kim KM, Lim YS, Lee HC. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. J Gastroenterol Hepatol. 2014;29:787-793. [PMID: 24224567 DOI: 10.1111/jgh.12452] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
328 Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Tominaga L, Kajiwara A, Kasuya K, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kozuka T, Kumada H. Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma. Liver Cancer 2020;9:756-70. [PMID: 33442544 DOI: 10.1159/000510299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
329 Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Tajiri N, Satani M, Niizeki T, Aino H, Okamura S, Iwamoto H. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. Cancer Med. 2015;4:1836-1843. [PMID: 26471348 DOI: 10.1002/cam4.548] [Cited by in Crossref: 29] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
330 Lee SS, Jeong SH, Byoun YS, Chung SM, Seong MH, Sohn HR, Min BY, Jang ES, Kim JW, Park GJ. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer. 2013;13:335. [PMID: 23829392 DOI: 10.1186/1471-2407-13-335] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
331 Abdel-Rahman O, Lamarca A. Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. Expert Rev Gastroenterol Hepatol. 2017;11:75-83. [PMID: 27882800 DOI: 10.1080/17474124.2017.1264874] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
332 Reginelli A, Vacca G, Segreto T, Picascia R, Clemente A, Urraro F, Serra N, Vanzulli A, Cappabianca S. Can microvascular invasion in hepatocellular carcinoma be predicted by diagnostic imaging? A critical review. Future Oncol 2018;14:2985-94. [PMID: 30084651 DOI: 10.2217/fon-2018-0175] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
333 Zheng J, Feng X, Liang Y, Cai J, Shi Z, Kirih MA, Tao L, Liang X. Safety and feasibility of laparoscopic liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a propensity score-matched study. Surg Endosc 2021;35:3267-78. [DOI: 10.1007/s00464-020-07763-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
334 Bargellini I, Bozzi E, Campani D, Carrai P, De Simone P, Pollina L, Cioni R, Filipponi F, Bartolozzi C. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol. 2013;82:e212-e218. [PMID: 23332890 DOI: 10.1016/j.ejrad.2012.12.009] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
335 Alexander LF, Harri P, Little B, Moreno CC, Mittal PK. Magnetic Resonance Imaging of Primary Hepatic Malignancies in Patients With and Without Chronic Liver Disease: A Pictorial Review. Cureus 2017;9:e1539. [PMID: 28989828 DOI: 10.7759/cureus.1539] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
336 Guo JH, Liu SX, Gao S, Kou FX, Zhang X, Wu D, Li XT, Chen H, Wang XD, Liu P, Zhang PJ, Xu HF, Cao G, Zhu LZ, Yang RJ, Zhu X. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. World J Gastroenterol 2020; 26(27): 3975-3988 [PMID: 32774071 DOI: 10.3748/wjg.v26.i27.3975] [Reference Citation Analysis]
337 Lin J, Chi MH, Zhang X, Weng SG. Correlation of postoperative splenic volume increase with prognosis of hepatocellular carcinoma after curative hepatectomy. Can J Surg 2019;62:418-25. [PMID: 31782297 DOI: 10.1503/cjs.015918] [Reference Citation Analysis]
338 Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol 2017; 8(6): 429-436 [PMID: 29291167 DOI: 10.5306/wjco.v8.i6.429] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 47] [Article Influence: 13.0] [Reference Citation Analysis]
339 Zeng DW, Dong J, Zhang JM, Zhu YY, Jiang JJ, Liu YR. HBeAg-negative chronic hepatitis patients should be monitored more strictly: a cross-sectional retrospective study on antiviral treatment-naïve patients. J Med Virol 2015;87:1682-8. [PMID: 25965250 DOI: 10.1002/jmv.24217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
340 Kim G, Shim JH, Kim M, Kim SY, Won HJ, Shin YM, Kim PN, Kim K, Lee S, Lee HC. Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas. British Journal of Surgery 2016;103:126-35. [DOI: 10.1002/bjs.9960] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
341 Lin ZX, Ruan DY, Jia CC, Wang TT, Cheng JT, Huang HQ, Wu XY. Controlling nutritional status (CONUT) score-based nomogram to predict overall survival of patients with HBV-associated hepatocellular carcinoma after curative hepatectomy. Clin Transl Oncol 2020;22:370-80. [PMID: 31201606 DOI: 10.1007/s12094-019-02137-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
342 Lee JI, Lee JW, Kim JM, Kim JK, Chung HJ, Kim YS. Prognosis of hepatocellular carcinoma expressing cytokeratin 19: Comparison with other liver cancers. World J Gastroenterol 2012; 18(34): 4751-4757 [PMID: 23002345 DOI: 10.3748/wjg.v18.i34.4751] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
343 Im JH, Yoon SM, Park HC, Kim JH, Yu JI, Kim TH, Kim JW, Nam TK, Kim K, Jang HS, Kim JH, Kim MS, Yoon WS, Jung I, Seong J. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. Liver Int. 2017;37:90-100. [PMID: 27317941 DOI: 10.1111/liv.13191] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
344 Carvalho SCR, Vasconcelos LRS, Fonseca LD, Carmo RF, Tomitão MT, Aroucha DCBL, Pereira LMMB, Stefano JT, Ribeiro-Júnior U, Oliveira CP, Carrilho FJ. Methylene tetrahydrofolate reductase (MTHFR) and vascular endothelial growth factor (VEGF) polymorphisms in Brazilian patients with Hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). Clinics (Sao Paulo) 2021;76:e2881. [PMID: 34644732 DOI: 10.6061/clinics/2021/e2881] [Reference Citation Analysis]
345 Ikeda K, Kawamura Y, Kobayashi M, Kominami Y, Fujiyama S, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma. Dig Dis Sci. 2017;62:2932-2942. [PMID: 28884320 DOI: 10.1007/s10620-017-4739-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 14.0] [Reference Citation Analysis]
346 Liang H, Xiong Z, Li R, Hu K, Cao M, Yang J, Zhong Z, Jia C, Yao Z, Deng M. BDH2 is downregulated in hepatocellular carcinoma and acts as a tumor suppressor regulating cell apoptosis and autophagy. J Cancer 2019;10:3735-45. [PMID: 31333791 DOI: 10.7150/jca.32022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
347 Aroucha DC, Carmo RF, Vasconcelos LRS, Lima RE, Mendonça TF, Arnez LE, Cavalcanti MDSM, Muniz MTC, Aroucha ML, Siqueira ER, Pereira LB, Moura P, Pereira LMMB, Coêlho MR. TNF-α and IL-10 polymorphisms increase the risk to hepatocellular carcinoma in HCV infected individuals: TNF-α and IL-10 Polymorphisms and HCC. J Med Virol 2016;88:1587-95. [DOI: 10.1002/jmv.24501] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
348 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 198] [Article Influence: 40.3] [Reference Citation Analysis]
349 Hu HT, Luo JP, Li HL, Guo CY, Yao QJ, Geng X, Jiang L. Transarterial chemoembolization combined with computed tomography-guided 125iodine implantation enhances survival in hepatocellular carcinoma patients with portal vein tumor thrombus. Oncotarget 2017;8:29258-68. [PMID: 28418927 DOI: 10.18632/oncotarget.16491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
350 Jeon MY, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Lee JH, Yu SJ, Kim YJ, Yoon JH, Cho EJ, Kim SU. Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. Gut Liver 2020;14:477-85. [PMID: 31640304 DOI: 10.5009/gnl19111] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
351 Leung C, Yeoh SW, Patrick D, Ket S, Marion K, Gow P, Angus PW. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol 2015; 21(4): 1189-1196 [PMID: 25632192 DOI: 10.3748/wjg.v21.i4.1189] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 62] [Article Influence: 11.5] [Reference Citation Analysis]
352 Zhang YF, Shang H, Zeng XL, Ji H, Li YM, Lu HW. Postoperative adjuvant chemo (embolization) therapy for hepatocellular carcinoma with portal vein tumor thrombosis. Onco Targets Ther 2018;11:5407-17. [PMID: 30214246 DOI: 10.2147/OTT.S171612] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
353 Kalva SP, Pectasides M, Liu R, Rachamreddy N, Surakanti S, Yeddula K, Ganguli S, Wicky S, Blaszkowsky LS, Zhu AX. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2014;37:381-387. [PMID: 23754191 DOI: 10.1007/s00270-013-0654-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
354 Rinaldi L, Nevola R, Franci G, Perrella A, Corvino G, Marrone A, Berretta M, Morone MV, Galdiero M, Giordano M, Adinolfi LE, Sasso FC. Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. Cancers (Basel) 2020;12:E1351. [PMID: 32466400 DOI: 10.3390/cancers12061351] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
355 Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist. 2014;19:394-402. [PMID: 24652387 DOI: 10.1634/theoncologist.2013-0114] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 12.3] [Reference Citation Analysis]
356 Qin L, Qin J, Lv X, Yin C, Zhang Q, Zhang J. MIF promoter polymorphism increases peripheral blood expression levels, contributing to increased susceptibility and poor prognosis in hepatocellular carcinoma. Oncol Lett 2021;22:549. [PMID: 34093770 DOI: 10.3892/ol.2021.12810] [Reference Citation Analysis]
357 Kim JW, Lee CH, Park YS, Seo TS, Song MG, Kim JH, Kim KA, Park CM. The value of paradoxical uptake of hepatocellular carcinoma on the hepatobiliary phase of gadoxetic acid-enhanced liver magnetic resonance imaging for the prediction of lipiodol uptake after transcatheter arterial chemoembolization. Eur J Radiol 2017;89:169-76. [PMID: 28267535 DOI: 10.1016/j.ejrad.2017.02.004] [Reference Citation Analysis]
358 Hatanaka T, Arai H, Shibasaki M, Tojima H, Takizawa D, Toyoda M, Takayama H, Abe T, Sato K, Kakizaki S. Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon-occluded transcatheter arterial chemoembolization: A retrospective cohort study. Hepatol Res. 2018;48:165-175. [PMID: 28500686 DOI: 10.1111/hepr.12912] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
359 Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer 2013;4:635-43. [PMID: 24155775 DOI: 10.7150/jca.7279] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 6.1] [Reference Citation Analysis]
360 Toyoda H, Kumada T, Tada T, Sone Y, Maeda A, Kaneoka Y. Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC. Hepatol Int. 2015;9:84-92. [PMID: 25788383 DOI: 10.1007/s12072-014-9553-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
361 Imedio ER, Beveridge RD, Urtasun JA, Campos GB, Estellés DL, Esparcia MF, Daroqui JC, Huerta ÁS, Ortiz AG, Salcedo JM. Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience. Med Oncol 2014;31:948. [PMID: 24740650 DOI: 10.1007/s12032-014-0948-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
362 Kim SU, Jung KS, Lee S, Park JY, Kim do Y, Ahn SH, Choi GH, Kim KS, Choi JS, Han KH. Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma. Liver Int. 2014;34:1008-1017. [PMID: 24483989 DOI: 10.1111/liv.12475] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
363 Ogawa K, Kamimura K, Watanabe Y, Motai Y, Kumaki D, Seki R, Sakamaki A, Abe S, Kawai H, Suda T, Yamagiwa S, Terai S. Effect of double platinum agents, combination of miriplatin-transarterial oily chemoembolization and cisplatin-hepatic arterial infusion chemotherapy, in patients with hepatocellular carcinoma: Report of two cases. World J Clin Cases 2017; 5(6): 238-246 [PMID: 28685137 DOI: 10.12998/wjcc.v5.i6.238] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
364 Kishore S, Friedman T, Madoff DC. Update on Embolization Therapies for Hepatocellular Carcinoma. Curr Oncol Rep 2017;19:40. [PMID: 28421483 DOI: 10.1007/s11912-017-0597-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
365 He M, Li Q, Shen J, Tan G, Li Q, Lai J, Wei W, Zhang Y, Zou R, Chen M, Guo R, Shi M. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. Cancer Med 2019;8:4200-13. [PMID: 31207163 DOI: 10.1002/cam4.2355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
366 Liang P, Yu J, Lu MD, Dong BW, Yu XL, Zhou XD, Hu B, Xie MX, Cheng W, He W, Jia JW, Lu GR. Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy. World J Gastroenterol 2013; 19(33): 5430-5438 [PMID: 24023485 DOI: 10.3748/wjg.v19.i33.5430] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 56] [Article Influence: 8.0] [Reference Citation Analysis]
367 Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624-1636. [PMID: 29107679 DOI: 10.1016/s1470-2045(17)30683-6] [Cited by in Crossref: 300] [Cited by in F6Publishing: 132] [Article Influence: 75.0] [Reference Citation Analysis]
368 Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146: 1691-700. e3. [PMID: 24583061 DOI: 10.1053/j.gastro.2014.02.032] [Cited by in Crossref: 339] [Cited by in F6Publishing: 328] [Article Influence: 48.4] [Reference Citation Analysis]
369 Weinmann A, Koch S, Sprinzl M, Kloeckner R, Schulze-bergkamen H, Düber C, Lang H, Otto G, Wörns MA, Galle PR. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. Liver Int 2015;35:591-600. [DOI: 10.1111/liv.12696] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
370 Khor AY, Toh Y, Allen JC, Ng DC, Kao YH, Zhu G, Choo SP, Lo RH, Tay KH, Teo JY, Goh BK, Burgmans MC, Irani FG, Goh AS, Chow PK. Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma. Hepatol Int 2014;8:395-404. [PMID: 26202641 DOI: 10.1007/s12072-014-9533-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
371 Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma 2020;7:117-31. [PMID: 32984089 DOI: 10.2147/JHC.S248314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
372 Chen P, Chiu N, Su C, Huang Y, Hou M, Lin H, Wu J. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. Journal of the Chinese Medical Association 2019;82:2-10. [DOI: 10.1097/jcma.0000000000000001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
373 Kulik L. Is radioembolization ready for the barcelona clinic liver cancer staging system? Hepatology 2010;52:1528-30. [DOI: 10.1002/hep.24030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
374 Lin K, Huang Q, Wang L, Zeng J, Ding Z, Liu H, Fu J, Guo P, Chen Z, Zeng Y, Zhou W, Liu J. Pre- and Postoperative Models for Prediction of Recurrence in Non-B, Non-C Hepatocellular Carcinoma. Front Oncol 2021;11:612588. [PMID: 33680963 DOI: 10.3389/fonc.2021.612588] [Reference Citation Analysis]
375 Li Q, Xing H, Liu D, Li H. Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma. World J Surg Oncol. 2015;13:294. [PMID: 26444667 DOI: 10.1186/s12957-015-0713-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
376 Fenoglio L, Serraino C, Castagna E, Cardellicchio A, Pomero F, Grosso M, Senore C. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World J Gastroenterol 2013; 19(21): 3207-3216 [PMID: 23745022 DOI: 10.3748/wjg.v19.i21.3207] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
377 Durham JD, Ray CE. How I do it: triaging patients with hepatocellular carcinoma. Semin Intervent Radiol 2012;29:64-8. [PMID: 23450921 DOI: 10.1055/s-0032-1302454] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
378 Feng YM, Feng CW, Lu CL, Lee MY, Chen CY, Chen SC. Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients. Jpn J Clin Oncol 2015;45:336-42. [PMID: 25646358 DOI: 10.1093/jjco/hyv007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
379 Tong CM, Ma S, Guan XY. Biology of hepatic cancer stem cells. J Gastroenterol Hepatol. 2011;26:1229-1237. [PMID: 21557770 DOI: 10.1111/j.1440-1746.2011.06762.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
380 Vietti Violi N, Duran R, Guiu B, Cercueil J, Aubé C, Digklia A, Pache I, Deltenre P, Knebel J, Denys A. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. The Lancet Gastroenterology & Hepatology 2018;3:317-25. [DOI: 10.1016/s2468-1253(18)30029-3] [Cited by in Crossref: 87] [Cited by in F6Publishing: 29] [Article Influence: 29.0] [Reference Citation Analysis]
381 Kim JM, Kwon CH, Joh JW, Ko JS, Park JB, Lee JH, Kim SJ, Paik SW, Park CK. C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion. World J Surg Oncol. 2013;11:92. [PMID: 23618082 DOI: 10.1186/1477-7819-11-92] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
382 He L, Cai X, Cheng S, Zhou H, Zhang Z, Ren J, Ren F, Yang Q, Tao N, Chen J. Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma. Oncol Lett 2019;17:5030-8. [PMID: 31186714 DOI: 10.3892/ol.2019.10174] [Reference Citation Analysis]
383 Ma XL, Shen MN, Hu B, Wang BL, Yang WJ, Lv LH, Wang H, Zhou Y, Jin AL, Sun YF, Zhang CY, Qiu SJ, Pan BS, Zhou J, Fan J, Yang XR, Guo W. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis. J Hematol Oncol 2019;12:37. [PMID: 30971294 DOI: 10.1186/s13045-019-0724-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 21.5] [Reference Citation Analysis]
384 Wan YM, Li YH, Xu ZY, Wu HM, Xu Y, Yang M, Wu XN. The Effect of Transarterial Chemoembolization in Combination With Kang'ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study. Integr Cancer Ther 2018;17:477-85. [PMID: 29108428 DOI: 10.1177/1534735417734913] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
385 Bruix J, Sherman M;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022. [PMID: 21374666 DOI: 10.1002/hep.24199] [Cited by in Crossref: 5422] [Cited by in F6Publishing: 5136] [Article Influence: 542.2] [Reference Citation Analysis]
386 Park Y, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Park YE, Park JH, Lee YI, Yun HR, Han KH. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int. 2016;36:100-107. [PMID: 26013186 DOI: 10.1111/liv.12878] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
387 Lee JC, Cheng CH, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC. Clinical relevance of alpha-fetoprotein in determining resection margin for hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e14827. [PMID: 30882667 DOI: 10.1097/MD.0000000000014827] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
388 Sapisochin G, Castells L, Dopazo C, Bilbao I, Minguez B, Lázaro JL, Allende H, Balsells J, Caralt M, Charco R. Single HCC in cirrhotic patients: liver resection or liver transplantation? Long-term outcome according to an intention-to-treat basis. Ann Surg Oncol. 2013;20:1194-1202. [PMID: 22965574 DOI: 10.1245/s10434-012-2655-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 7.0] [Reference Citation Analysis]
389 Zhang YF, Shi M, Lu LH, Wang L, Guo RP. Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models. J Hepatocell Carcinoma 2021;8:253-61. [PMID: 33907695 DOI: 10.2147/JHC.S305581] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
390 Feng LH, Sun HC, Zhu XD, Liu XF, Zhang SZ, Li XL, Li Y, Tang ZY. Prognostic nomograms and risk classifications of outcomes in very early-stage hepatocellular carcinoma patients after hepatectomy. Eur J Surg Oncol 2021;47:681-9. [PMID: 33189491 DOI: 10.1016/j.ejso.2020.10.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Cucchetti A, Cescon M, Trevisani F, Morelli MC, Ercolani G, Pellegrini S, Erroi V, Bigonzi E, Pinna AD. What is the probability of being too old for salvage transplantation after hepatocellular carcinoma resection? Dig Liver Dis. 2012;44:523-529. [PMID: 22387286 DOI: 10.1016/j.dld.2012.01.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
392 El-Khoueiry A, Posey JA, Castillo Ferrando JR, Krishnamurthi SS, Syed S, Kollia G, Walters I, Fischer BS, Masson E. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases. Cancer Chemother Pharmacol. 2013;72:53-64. [PMID: 23719718 DOI: 10.1007/s00280-013-2168-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
393 Deipolyi AR, Oklu R, Al-Ansari S, Zhu AX, Goyal L, Ganguli S. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2015;26:516-522. [PMID: 25704226 DOI: 10.1016/j.jvir.2014.12.020] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 6.5] [Reference Citation Analysis]
394 Belghiti J, Fuks D. Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer. 2012;1:71-82. [PMID: 24159575 DOI: 10.1159/00034240] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
395 Kim GA, Shim JH, Yoon SM, Jung J, Kim JH, Ryu MH, Ryoo BY, Kang YK, Lee D, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. J Vasc Interv Radiol. 2015;26:320-9.e6. [PMID: 25612807 DOI: 10.1016/j.jvir.2014.10.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
396 Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Matejka J, Stauber R, Buder R, Grünberger B, Schöniger-Hekele M, Müller C, Peck-Radosavljevic M. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011;34:949-59. [PMID: 21883324 DOI: 10.1111/j.1365-2036.2011.04823.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
397 Yuan P, Fu C, Yang Y, Adila A, Zhou F, Wei X, Wang W, Lv J, Li Y, Xia L, Li J. Cistanche tubulosa Phenylethanoid Glycosides Induce Apoptosis of Hepatocellular Carcinoma Cells by Mitochondria-Dependent and MAPK Pathways and Enhance Antitumor Effect through Combination with Cisplatin. Integr Cancer Ther 2021;20:15347354211013085. [PMID: 33949239 DOI: 10.1177/15347354211013085] [Reference Citation Analysis]
398 Op den Winkel M, Nagel D, Op den Winkel P, Trojan J, Paprottka PM, Steib CJ, Schmidt L, Göller M, Stieber P, Göhring P, Herbst A, Rentsch M, De Toni EN, Göke B, Gerbes AL, Kolligs FT. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score. Eur J Gastroenterol Hepatol 2018;30:44-53. [PMID: 29076939 DOI: 10.1097/MEG.0000000000001005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
399 Nakamura Y, Kawaoka T, Higaki T, Fukumoto W, Honda Y, Iida M, Fujioka C, Kiguchi M, Aikata H, Chayama K, Awai K. Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival. Eur J Radiol 2018;98:41-9. [PMID: 29279169 DOI: 10.1016/j.ejrad.2017.10.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
400 Bell R, Pandanaboyana S, Lodge JPA, Prasad KR, Jones R, Hidalgo E. Primary liver resection for patients with cirrhosis and hepatocellular carcinoma: the role of surgery in BCLC early (A) and intermediate stages (B). Langenbecks Arch Surg. 2017;402:575-583. [PMID: 27456677 DOI: 10.1007/s00423-016-1475-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
401 Liu F, Chen M, Mei J, Xu L, Guo R, Lin X, Zhang Y, Peng Z. Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma. J Oncol 2019;2019:6298502. [PMID: 31636667 DOI: 10.1155/2019/6298502] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
402 Zhang Y, Fan W, Wang Y, Huang G, Li J. Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study. Cancer Control. 2019;26:1073274819872216. [PMID: 31466465 DOI: 10.1177/1073274819872216] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
403 Liu X, Yu L, Han C, Lu S, Zhu G, Su H, Qin W, Liao X, Peng T. Polymorphisms of HLA-DQB1 predict survival of hepatitis B virus-related hepatocellular carcinoma patients receiving hepatic resection. Clin Res Hepatol Gastroenterol 2016;40:739-47. [PMID: 27288300 DOI: 10.1016/j.clinre.2016.04.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
404 Knox JJ. Addressing the Interplay of Liver Disease and Hepatocellular Carcinoma on Patient Survival: The ALBI Scoring Model. JCO 2015;33:529-31. [DOI: 10.1200/jco.2014.59.0521] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
405 Xu L, Wu J, Lu W, Yang C, Liu H. Application of the Albumin-Bilirubin Grade in Predicting the Prognosis of Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Transplant Proc. 2019;51:3338-3346. [PMID: 31732203 DOI: 10.1016/j.transproceed.2019.08.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
406 Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58. [PMID: 20628345 DOI: 10.1038/nrgastro.2010.100] [Cited by in Crossref: 810] [Cited by in F6Publishing: 813] [Article Influence: 73.6] [Reference Citation Analysis]
407 Li MX, Bi XY, Li ZY, Huang Z, Han Y, Zhou JG, Zhao JJ, Zhang YF, Zhao H, Cai JQ. Prognostic Role of Glasgow Prognostic Score in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2015;94:e2133. [PMID: 26656342 DOI: 10.1097/MD.0000000000002133] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
408 Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56:1384-91. [PMID: 22326465 DOI: 10.1016/j.jhep.2011.10.027] [Cited by in Crossref: 536] [Cited by in F6Publishing: 503] [Article Influence: 59.6] [Reference Citation Analysis]
409 Lee SK, Jang JW, Nam H, Sung PS, Kim HY, Kwon JH, Lee SW, Song DS, Kim CW, Song MJ, Choi HJ, You YK, Bae SH, Choi JY, Yoon SK. Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation. Hepatol Int 2021;15:137-45. [PMID: 33496932 DOI: 10.1007/s12072-020-10131-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
410 Harada N, Shirabe K, Maeda T, Kayashima H, Takaki S, Maehara Y. Comparison of the Outcomes of Patients with Hepatocellular Carcinoma and Portal Hypertension After Liver Resection Versus Radiofrequency Ablation. World J Surg 2016;40:1709-19. [DOI: 10.1007/s00268-016-3465-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
411 Jacob R, Turley F, Redden DT, Saddekni S, Aal AK, Keene K, Yang E, Zarzour J, Bolus D, Smith JK. Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 cm. HPB (Oxford). 2015;17:140-149. [PMID: 25186290 DOI: 10.1111/hpb.12331] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
412 El-Fattah MA, Aboelmagd M, Elhamouly M. Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study. United European Gastroenterol J 2017;5:227-35. [PMID: 28344790 DOI: 10.1177/2050640616659024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
413 Lee SW, Tung CF, Peng YC, Lien HC, Chang CS. Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population. J Dig Dis 2020;21:462-7. [PMID: 32472590 DOI: 10.1111/1751-2980.12911] [Reference Citation Analysis]
414 Taylor AC, Maddirela D, White SB. Role of Radioembolization for Biliary Tract and Primary Liver Cancer. Surgical Oncology Clinics of North America 2019;28:731-43. [DOI: 10.1016/j.soc.2019.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
415 Quencer KB, Friedman T, Sheth R, Oklu R. Tumor thrombus: incidence, imaging, prognosis and treatment. Cardiovasc Diagn Ther 2017;7:S165-77. [PMID: 29399520 DOI: 10.21037/cdt.2017.09.16] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 12.5] [Reference Citation Analysis]
416 Lee CW, Yu MC, Wang CC, Lee WC, Tsai HI, Kuan FC, Chen CW, Hsieh YC, Chen HY. Liver resection for hepatocellular carcinoma larger than 10 cm: A multi-institution long-term observational study. World J Gastrointest Surg 2021; 13(5): 476-492 [PMID: 34122737 DOI: 10.4240/wjgs.v13.i5.476] [Reference Citation Analysis]
417 Leng JJ, Xu YZ, Dong JH. Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis. ANZ J Surg. 2016;86:816-820. [PMID: 25088384 DOI: 10.1111/ans.12803] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
418 Ruiz E, Rojas Rojas T, Berrospi F, Chávez I, Luque C, Cano L, Doimi F, Pineau P, Deharo E, Bertani S. Hepatocellular carcinoma surgery outcomes in the developing world: A 20-year retrospective cohort study at the National Cancer Institute of Peru. Heliyon 2016;2:e00052. [PMID: 27441236 DOI: 10.1016/j.heliyon.2015.e00052] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
419 Di Sandro S, Benuzzi L, Lauterio A, Botta F, De Carlis R, Najjar M, Centonze L, Danieli M, Pezzoli I, Rampoldi A, Bagnardi V, De Carlis L. Single Hepatocellular Carcinoma approached by curative-intent treatment: A propensity score analysis comparing radiofrequency ablation and liver resection. European Journal of Surgical Oncology 2019;45:1691-9. [DOI: 10.1016/j.ejso.2019.04.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
420 Kim JH, Shim JH, Lee HC, Sung KB, Ko HK, Ko GY, Gwon DI, Kim JW, Lim YS, Park SH. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver Int. 2017;37:1861-1868. [PMID: 28581250 DOI: 10.1111/liv.13487] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
421 Chong JU, Choi GH, Han DH, Kim KS, Seong J, Han K, Choi JS. Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Ann Surg Oncol 2018;25:3308-15. [DOI: 10.1245/s10434-018-6653-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
422 Wang ZX, Li J, Wang EX, Xia DD, Bai W, Wang QH, Yuan J, Li XM, Niu J, Yin ZX, Xia JL, Fan DM, Han GH. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization. World J Gastroenterol 2020; 26(15): 1805-1819 [PMID: 32351295 DOI: 10.3748/wjg.v26.i15.1805] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
423 Mehta AS, Lau DT, Wang M, Aslam A, Nasir B, Javaid A, Poongkunran M, Block TM. Application of the Doylestown algorithm for the early detection of hepatocellular carcinoma. PLoS One 2018;13:e0203149. [PMID: 30169533 DOI: 10.1371/journal.pone.0203149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
424 Leoni S, Piscaglia F, Serio I, Terzi E, Pettinari I, Croci L, Marinelli S, Benevento F, Golfieri R, Bolondi L. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. Dig Liver Dis. 2014;46:549-555. [PMID: 24630947 DOI: 10.1016/j.dld.2014.02.012] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
425 Azuma S, Asahina Y, Nishimura-sakurai Y, Kakinuma S, Kaneko S, Nagata H, Goto F, Ootani S, Kawai-kitahata F, Taniguchi M, Murakawa M, Watanabe T, Tasaka-fujita M, Itsui Y, Nakagawa M, Watanabe M. Efficacy of additional radiofrequency ablation after transcatheter arterial chemoembolization for intermediate hepatocellular carcinoma: Additional RFA after TACE for intermediate HCC. Hepatol Res 2016;46:312-9. [DOI: 10.1111/hepr.12566] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
426 Kalra N, Kang M, Bhatia A, Duseja AK, Dhiman RK, Arya VK, Rajwanshi A, Chawla YK, Khandelwal N. Role of radiofrequency ablation in unresectable hepatocellular carcinoma: An Indian experience. Indian J Radiol Imaging. 2013;23:139-144. [PMID: 24082478 DOI: 10.4103/0971-3026.116569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
427 Akada K, Koyama N, Taniguchi S, Miura Y, Aoshima K. Database analysis of patients with hepatocellular carcinoma and treatment flow in early and advanced stages. Pharmacol Res Perspect. 2019;7:e00486. [PMID: 31249691 DOI: 10.1002/prp2.486] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
428 Shao S, Liang Y, Kuang S, Chen J, Shan Q, Yang H, Zhang Y, Wang B, J Fowler K, Wang J, B Sirlin C. Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection. Bosn J Basic Med Sci 2020;20:401-10. [PMID: 31999940 DOI: 10.17305/bjbms.2019.4576] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
429 Wang P, Tan G, Zhu M, Li W, Zhai B, Sun X. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;12:1-8. [PMID: 28847184 DOI: 10.1080/17474124.2017.1373018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
430 Molvar C, Lewandowski RJ. Intra-Arterial Therapies for Liver Masses. Radiologic Clinics of North America 2015;53:973-84. [DOI: 10.1016/j.rcl.2015.05.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
431 Delicque J, Boulin M, Guiu B, Pelage J, Escal L, Schembri V, Assenat E, Fohlen A. Interventional oncology for hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 2016;40:530-7. [DOI: 10.1016/j.clinre.2016.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
432 Swaid F, Geller DA. Minimally Invasive Primary Liver Cancer Surgery. Surgical Oncology Clinics of North America 2019;28:215-27. [DOI: 10.1016/j.soc.2018.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
433 Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Interventional therapies for hepatocellular carcinoma. Cancer Imaging 2012;12:79-88. [PMID: 22487698 DOI: 10.1102/1470-7330.2012.0011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
434 Bailey CW, Sydnor MK Jr. Current State of Tumor Ablation Therapies. Dig Dis Sci 2019;64:951-8. [PMID: 30859403 DOI: 10.1007/s10620-019-05514-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
435 Zhang Q, Zhang CS, Xin Q, Ma Z, Liu GQ, Liu BB, Wang FM, Gao YT, Du Z. Perinodular ductular reaction/epithelial cell adhesion molecule loss in small hepatic nodules. World J Gastroenterol 2014; 20(31): 10908-10915 [PMID: 25152593 DOI: 10.3748/wjg.v20.i31.10908] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
436 Zhang W, Liu C, Tan Y, Jiang L, Yan L, Yang J, Wen T. Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: A propensity-matching cohort study. International Journal of Surgery 2018;54:259-64. [DOI: 10.1016/j.ijsu.2018.03.051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
437 Sangiovanni A, Colombo M. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2016;36 Suppl 1:124-129. [PMID: 26725909 DOI: 10.1111/liv.13028] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
438 Zhang YF, Zhou J, Wei W, Zou RH, Chen MS, Lau WY, Shi M, Guo RP. Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making. Br J Cancer. 2016;115:1039-1047. [PMID: 27701389 DOI: 10.1038/bjc.2016.301] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
439 Vilana R, Forner A, García Á, Ayuso C, Bru C. Carcinoma hepatocelular: diagnóstico, estadificación y estrategia terapéutica. Radiología 2010;52:385-98. [DOI: 10.1016/j.rx.2010.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
440 Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma. ESMO Open 2021;6:100020. [PMID: 33399083 DOI: 10.1016/j.esmoop.2020.100020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
441 Habbel VSA, Zeile M, Stavrou GA, Wacker F, Brüning R, Oldhafer KJ, Rodt T. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma. Abdom Radiol (NY) 2019;44:3463-79. [PMID: 31332502 DOI: 10.1007/s00261-019-02128-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
442 Deng R, Cui X, Dong Y, Tang Y, Tao X, Wang S, Wang J, Chen L. Construction of circRNA-Based ceRNA Network to Reveal the Role of circRNAs in the Progression and Prognosis of Hepatocellular Carcinoma. Front Genet 2021;12:626764. [PMID: 33719338 DOI: 10.3389/fgene.2021.626764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
443 Pang EH, Harris AC, Chang SD. Approach to the Solitary Liver Lesion: Imaging and When to Biopsy. Can Assoc Radiol J 2016;67:130-48. [DOI: 10.1016/j.carj.2015.07.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
444 Chung JW, Kim BH, Lee CS, Kim GH, Sohn HR, Min BY, Song JC, Park HK, Jang ES, Yoon H, Kim J, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Lee J, Ahn S, Kim JW. Optimizing Surveillance Performance of Alpha-Fetoprotein by Selection of Proper Target Population in Chronic Hepatitis B. PLoS One 2016;11:e0168189. [PMID: 27997559 DOI: 10.1371/journal.pone.0168189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
445 Hyun D, Shin SW, Cho SK, Park KB, Park HS, Choo SW, Do YS, Choo I, Shin J, Lim S. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. Acta Radiol 2015;56:1437-45. [DOI: 10.1177/0284185114560937] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
446 Liao M, Zhong X, Zhang J, Liu Y, Zhu Z, Wu H, Zeng Y, Huang J. Radiofrequency ablation using a 10-mm target margin for small hepatocellular carcinoma in patients with liver cirrhosis: A prospective randomized trial. J Surg Oncol 2017;115:971-9. [PMID: 28334430 DOI: 10.1002/jso.24607] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
447 Lu XJ, Dong J, Ji LJ, Xiao LX, Ling CQ, Zhou J. Tolerability and efficacy of gamma knife radiosurgery on hepatocellular carcinoma with portal vein tumor thrombosis. Oncotarget. 2016;7:3614-3622. [PMID: 26473291 DOI: 10.18632/oncotarget.6118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
448 Galuppo R, Ramaiah D, Ponte OM, Gedaly R. Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci. 2014;59:1688-1697. [PMID: 24573715 DOI: 10.1007/s10620-014-3058-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
449 Fukubayashi K, Tanaka M, Izumi K, Watanabe T, Fujie S, Kawasaki T, Yoshimaru Y, Tateyama M, Setoyama H, Naoe H. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method. Cancer Med. 2015;4:1214-1223. [PMID: 26044168 DOI: 10.1002/cam4.476] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
450 Liu Y, Huang W, He M, Lian H, Guo Y, Huang J, Zhou J, Zhu K. Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in Barcelona Clinic Liver Cancer Stage C Patients. Oncol Res 2019;27:565-73. [PMID: 30005719 DOI: 10.3727/096504018X15313896322888] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
451 Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis. Hepatol Commun 2020;4:1218-28. [PMID: 32766480 DOI: 10.1002/hep4.1535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
452 Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Seminars in Diagnostic Pathology 2017;34:153-9. [DOI: 10.1053/j.semdp.2016.12.011] [Cited by in Crossref: 153] [Cited by in F6Publishing: 162] [Article Influence: 38.3] [Reference Citation Analysis]
453 Hyun D, Cho SK, Shin SW, Park KB, Lee SY, Park HS, Do YS. Combined transarterial chemoembolization and radiofrequency ablation for small treatment-naïve hepatocellular carcinoma infeasible for ultrasound-guided radiofrequency ablation: long-term outcomes. Acta Radiol 2018;59:773-81. [PMID: 29034691 DOI: 10.1177/0284185117735349] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
454 Czaja AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58:1459-1476. [PMID: 23306849 DOI: 10.1007/s10620-012-2525-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
455 Jin P, Shao S, Wu W, Zhao X, Huang B, Fu Q, Que R, Hu Q. Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis. Japanese Journal of Clinical Oncology 2018;48:1058-69. [DOI: 10.1093/jjco/hyy138] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
456 Lee SW, Lee TY, Cheng YC, Yen CL, Yang SS. The correlation with tumor radiological characteristics and prognosis of patients with early-stage hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Medicine (Baltimore) 2021;100:e26414. [PMID: 34190159 DOI: 10.1097/MD.0000000000026414] [Reference Citation Analysis]
457 Meng XC, Chen BH, Huang JJ, Huang WS, Cai MY, Zhou JW, Guo YJ, Zhu KS. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib. World J Gastroenterol 2018; 24(4): 484-493 [PMID: 29398869 DOI: 10.3748/wjg.v24.i4.484] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
458 Minici R, Ammendola M, Manti F, Siciliano MA, Minici M, Komaei I, Currò G, Laganà D. Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9. Front Pharmacol 2021;12:634087. [PMID: 33897422 DOI: 10.3389/fphar.2021.634087] [Reference Citation Analysis]
459 Fuji T, Nakamura Y, Fukumoto W, Kajiwara K, Chosa K, Tani C, Matsubara Y, Terada H, Honda Y, Arihiro K, Iida M, Baba Y, Awai K. Clinical Indication for Computed Tomography During Hepatic Arteriography (CTHA) in Addition to Dynamic CT Studies to Identify Hypervascularity of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2018;41:618-27. [PMID: 29101449 DOI: 10.1007/s00270-017-1832-9] [Reference Citation Analysis]
460 White JA, Gray SH, Li P, Simpson HN, McGuire BM, Eckhoff DE, Abdel Aal AMK, Saddekni S, Dubay DA. Current guidelines for chemoembolization for hepatocellular carcinoma: Room for improvement? Hepatol Commun 2017;1:338-46. [PMID: 29404463 DOI: 10.1002/hep4.1046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
461 Elzouki AN, Elkhider H, Yacout K, Al Muzrakchi A, Al-Thani S, Ismail O. Metastatic hepatocellular carcinoma to parotid glands. Am J Case Rep 2014;15:343-7. [PMID: 25129420 DOI: 10.12659/AJCR.890661] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
462 Zhang YQ, Guo JS. Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2015; 21(13): 3860-3866 [PMID: 25852270 DOI: 10.3748/wjg.v21.i13.3860] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
463 Chen J, Peng K, Hu D, Shen J, Zhou Z, Xu L, Chen J, Pan Y, Wang J, Zhang Y, Chen M. Tumor Location Influences Oncologic Outcomes of Hepatocellular Carcinoma Patients Undergoing Radiofrequency Ablation. Cancers (Basel). 2018;10. [PMID: 30309001 DOI: 10.3390/cancers10100378] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
464 Franssen B, Jibara G, Tabrizian P, Schwartz ME, Roayaie S. Actual 10-year survival following hepatectomy for hepatocellular carcinoma. HPB (Oxford) 2014;16:830-5. [PMID: 24372853 DOI: 10.1111/hpb.12206] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
465 Zhong JH, Xiang BD, Gong WF, Ke Y, Mo QG, Ma L, Liu X, Li LQ. Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One. 2013;8:e68193. [PMID: 23874536 DOI: 10.137/journal.pone.0068193] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
466 Zhuang H, Zhou Z, Ma Z, Huang S, Gong Y, Zhang Z, Hou B, Yu W, Zhang C. Prognostic Stratification Based on a Novel Nomogram for Solitary Large Hepatocellular Carcinoma After Curative Resection. Front Oncol 2020;10:556489. [PMID: 33312945 DOI: 10.3389/fonc.2020.556489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
467 Yin W, Ye Q, Wang F, Liang J, Xu B, Zhang X, Zhang Q, Liu Y, Li G, Han T. ART score and hepatocellular carcinoma: An appraisal of its applicability. Clin Res Hepatol Gastroenterol 2016;40:705-14. [PMID: 27289168 DOI: 10.1016/j.clinre.2016.05.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
468 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 94] [Article Influence: 21.6] [Reference Citation Analysis]
469 Zhang G, Wang Z, Luo W, Jiao H, Wu J, Jiang C. Expression of Potential Cancer Stem Cell Marker ABCG2 is Associated with Malignant Behaviors of Hepatocellular Carcinoma. Gastroenterol Res Pract 2013;2013:782581. [PMID: 24194752 DOI: 10.1155/2013/782581] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
470 王涛, 王凤梅, 高英堂, 朱争艳, 郭洪生, 杨斌, 张传山, 张勤, 杜智. 磷脂酰肌醇蛋白聚糖3在肝穿刺活检标本中鉴别诊断的意义. 世界华人消化杂志 2011; 19(7): 693-699 [DOI: 10.11569/wcjd.v19.i7.693] [Reference Citation Analysis]
471 Barbier-Torres L, Beraza N, Fernández-Tussy P, Lopitz-Otsoa F, Fernández-Ramos D, Zubiete-Franco I, Varela-Rey M, Delgado TC, Gutiérrez V, Anguita J, Pares A, Banales JM, Villa E, Caballería J, Alvarez L, Lu SC, Mato JM, Martínez-Chantar ML. Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1. Hepatology 2015;62:1237-48. [PMID: 26109312 DOI: 10.1002/hep.27959] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
472 Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev. 2018;68:16-24. [PMID: 29783126 DOI: 10.1016/j.ctrv.2018.05.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 22.7] [Reference Citation Analysis]
473 Voron T, Tselikas L, Pietrasz D, Pigneur F, Laurent A, Compagnon P, Salloum C, Luciani A, Azoulay D. Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma. Ann Surg 2015;261:1173-83. [PMID: 24950264 DOI: 10.1097/SLA.0000000000000743] [Cited by in Crossref: 174] [Cited by in F6Publishing: 85] [Article Influence: 34.8] [Reference Citation Analysis]
474 Xu H, Mao Y. A brief comment on liver resection for hepatocellular carcinoma. Gastroenterol Rep (Oxf) 2013;1:184-5. [PMID: 24759963 DOI: 10.1093/gastro/got019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
475 Elemeery MN, Mohamed MA, Madkour MA, Shamseya MM, Issa NM, Badr AN, Ghareeb DA, Pan CH. MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes. World J Gastroenterol 2019; 25(42): 6322-6341 [PMID: 31754293 DOI: 10.3748/wjg.v25.i42.6322] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
476 Jung SW, Park NH, Shin JW, Park BR, Kim CJ, Lee JE, Shin ES, Kim JA, Chung YH. Prognostic impact of telomere maintenance gene polymorphisms on hepatocellular carcinoma patients with chronic hepatitis B. Hepatology. 2014;59:1912-1920. [PMID: 23907815 DOI: 10.1002/hep.26655] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
477 Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, Romano A, Cicorelli A, Tumino E, Federici G, Cioni R. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol. 2012;81:1173-1178. [PMID: 21466931 DOI: 10.1016/j.ejrad.2011.03.046] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
478 Chalasani NP, Ramasubramanian TS, Bhattacharya A, Olson MC, Edwards V DK, Roberts LR, Kisiel JB, Reddy KR, Lidgard GP, Johnson SC, Bruinsma JJ. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020;. [PMID: 32889146 DOI: 10.1016/j.cgh.2020.08.065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
479 Marquez HP, Karalli A, Haubenreisser H, Mathew RP, Alkadhi H, Brismar TB, Henzler T, Fischer MA. Computed tomography perfusion imaging for monitoring transarterial chemoembolization of hepatocellular carcinoma. Eur J Radiol 2017;91:160-7. [PMID: 28629564 DOI: 10.1016/j.ejrad.2017.03.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
480 Božin T, Mustapić S, Bokun T, Patrlj L, Rakić M, Aralica G, Kujundžić M, Trkulja V, Grgurević I. Albi Score as a Predictor of Survival in Patients with Compensated Cirrhosis Resected for Hepatocellular Carcinoma: Exploratory Evaluation in Relationship to Palbi and Meld Liver Function Scores. Acta Clin Croat 2018;57:292-300. [PMID: 30431722 DOI: 10.20471/acc.2018.57.02.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
481 Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Trauner M, Peck-radosavljevic M. The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013;57:2261-73. [DOI: 10.1002/hep.26256] [Cited by in Crossref: 182] [Cited by in F6Publishing: 175] [Article Influence: 22.8] [Reference Citation Analysis]
482 Zhu D, Yuan D, Wang Z, Chen S. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients. Medicine (Baltimore). 2019;98:e15682. [PMID: 31261491 DOI: 10.1097/md.0000000000015682] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
483 El-Badrawy A. MDCT evaluation of synchronous breast carcinoma and other solid malignancies. Breast Dis 2021. [PMID: 34120894 DOI: 10.3233/BD-201065] [Reference Citation Analysis]
484 op den Winkel M, Nagel D, Sappl J, op den Winkel P, Lamerz R, Zech CJ, Straub G, Nickel T, Rentsch M, Stieber P. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One. 2012;7:e45066. [PMID: 23071507 DOI: 10.1371/journal.pone.0045066] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
485 Funaoka A, Numata K, Takeda A, Saigusa Y, Tsurugai Y, Nihonmatsu H, Chuma M, Fukuda H, Okada M, Nakano M, Maeda S. Use of Contrast-Enhanced Ultrasound with Sonazoid for Evaluating the Radiotherapy Efficacy for Hepatocellular Carcinoma. Diagnostics (Basel) 2021;11:486. [PMID: 33803373 DOI: 10.3390/diagnostics11030486] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
486 Luz JH, Luz PM, Martin HS, Gouveia HR, Levigard RB, Nogueira FD, Rodrigues BC, de Miranda TN, Mamede MH. DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center. Cancer Imaging 2017;17:5. [PMID: 28166821 DOI: 10.1186/s40644-017-0108-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
487 Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study. Mol Clin Oncol 2017;7:1013-20. [PMID: 29285366 DOI: 10.3892/mco.2017.1442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
488 Nouri YM, Kim JH, Yoon HK, Ko HK, Shin JH, Gwon DI. Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma. Korean J Radiol 2019;20:34-49. [PMID: 30627020 DOI: 10.3348/kjr.2018.0088] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
489 Yu JI, Park HC, Lim do H, Kim CJ, Oh D, Yoo BC, Paik SW, Kho KC, Lee JH. Scheduled interval trans-catheter arterial chemoembolization followed by radiation therapy in patients with unresectable hepatocellular carcinoma. J Korean Med Sci. 2012;27:736-743. [PMID: 22787367 DOI: 10.3346/jkms.2012.27.7.736] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
490 Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Sakata K, Matsugaki S, Kajiwara M, Fukuizumi K, Tajiri N, Matsukuma N. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma. Oncology. 2013;84:108-114. [PMID: 23147476 DOI: 10.1159/000342650] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
491 Kim HY, Park J, Joo J, Kim H, Woo SM, Lee WJ, Kim C. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma: Outcome of sorafenib therapy in cirrhosis. J Gastroenterol Hepatol 2013;28:1756-61. [DOI: 10.1111/jgh.12310] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
492 Chen S, Gao Y, Li Z, Jia J, Fang M, Wang M, Feng H, Chen Q, Guan W, Wang Z, Gao C. A Nomogram Predicting Extrahepatic Metastases for Patients with Adjuvant Transarterial Chemoembolization after Hepatectomy. J Cancer 2018;9:4223-33. [PMID: 30519323 DOI: 10.7150/jca.25886] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
493 Battaglia V, Cervelli R. Liver investigations: Updating on US technique and contrast-enhanced ultrasound (CEUS). Eur J Radiol. 2017;96:65-73. [PMID: 29103478 DOI: 10.1016/j.ejrad.2017.08.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
494 Wang ZX, Jiang CP, Cao Y, Zhang G, Chen WB, Ding YT. Preoperative serum liver enzyme markers for predicting early recurrence after curative resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2015;14:178-85. [PMID: 25865691 DOI: 10.1016/s1499-3872(15)60353-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
495 Weledji EP, Enow Orock G, Ngowe MN, Nsagha DS. How grim is hepatocellular carcinoma? Ann Med Surg (Lond) 2014;3:71-6. [PMID: 25568791 DOI: 10.1016/j.amsu.2014.06.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
496 Toyoda H, Tada T, Tsuji K, Hiraoka A, Tachi Y, Itobayashi E, Takaguchi K, Senoh T, Takizawa D, Ishikawa T, Kumada T. Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan: Outcomes of HCC after SVR. Hepatol Res 2016;46:734-42. [DOI: 10.1111/hepr.12613] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
497 Bargellini I, Battaglia V, Caramella D, Bartolozzi C. Imaging in Hepatocellular Carcinoma: Radiologic Assessment. In: Berliner L, Lemke HU, editors. An Information Technology Framework for Predictive, Preventive and Personalised Medicine. Cham: Springer International Publishing; 2015. pp. 33-44. [DOI: 10.1007/978-3-319-12166-6_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
498 Elsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, Masch WR, Marks RM, Kamaya A, Do RKG, Kono Y, Fowler KJ, Tang A, Bashir MR, Hecht EM, Jambhekar K, Lyshchik A, Rodgers SK, Heiken JP, Kohli M, Fetzer DT, Wilson SR, Kassam Z, Mendiratta-Lala M, Singal AG, Lim CS, Cruite I, Lee J, Ash R, Mitchell DG, McInnes MDF, Sirlin CB. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance.J Hepatocell Carcinoma. 2019;6:49-69. [PMID: 30788336 DOI: 10.2147/JHC.S186239] [Cited by in Crossref: 42] [Cited by in F6Publishing: 13] [Article Influence: 21.0] [Reference Citation Analysis]
499 Kim SE, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center. Korean J Hepatol. 2011;17:113-119. [PMID: 21757982 DOI: 10.3350/kjhep.2011.17.2.113] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
500 Choi TW, Kim HC, Lee JH, Yu SJ, Kang B, Hur S, Lee M, Jae HJ, Chung JW. The Safety and Clinical Outcomes of Chemoembolization in Child-Pugh Class C Patients with Hepatocellular Carcinomas. Korean J Radiol. 2015;16:1283-1293. [PMID: 26576118 DOI: 10.3348/kjr.2015.16.6.1283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
501 Yoon JS, Sinn DH, Lee JH, Kim HY, Lee CH, Kim SW, Lee HY, Nam JY, Chang Y, Lee YB, Cho EJ, Yu SJ, Kim HC, Chung JW, Kim YJ, Yoon JH. Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. Cancers (Basel) 2019;11:E1721. [PMID: 31689972 DOI: 10.3390/cancers11111721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
502 Richtig G, Aigelsreiter A, Schwarzenbacher D, Ress AL, Adiprasito JB, Stiegelbauer V, Hoefler G, Schauer S, Kiesslich T, Kornprat P, Winder T, Eisner F, Gerger A, Stoeger H, Stauber R, Lackner C, Pichler M. SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types. PLoS One 2017;12:e0187814. [PMID: 29121666 DOI: 10.1371/journal.pone.0187814] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
503 Dai QS, Gu HL, Ye S, Zhang YJ, Lin XJ, Lau WY, Peng ZW, Chen MS. Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study. Mol Clin Oncol. 2014;2:1047-1054. [PMID: 25279196 DOI: 10.3892/mco.2014.391] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
504 Hartenbach M, Weber S, Pilz M, Hartenbach S, Zacherl MJ, Paprottka PM, Tiling R, Bartenstein P, Hacker M, Haug AR, Albert NL. Combined [18F]-Fluoroethylcholine PET/CT and 99mTc-Macroaggregated Albumin SPECT/CT Predict Survival in Patients With Intermediate-Stage Hepatocellular Carcinoma. Clin Nucl Med 2018;43:477-81. [PMID: 29659390 DOI: 10.1097/RLU.0000000000002092] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
505 Serenari M, Cescon M, Cucchetti A, Pinna AD. Liver function impairment in liver transplantation and after extended hepatectomy. World J Gastroenterol 2013; 19(44): 7922-7929 [PMID: 24307786 DOI: 10.3748/wjg.v19.i44.7922] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
506 Yoon JH, Goo YJ, Lim CJ, Choi SK, Cho SB, Shin SS, Jun CH. Features of extrahepatic metastasis after radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol 2020; 26(32): 4833-4845 [PMID: 32921960 DOI: 10.3748/wjg.v26.i32.4833] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
507 Rodríguez-perálvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability. Ann Surg Oncol 2013;20:325-39. [DOI: 10.1245/s10434-012-2513-1] [Cited by in Crossref: 257] [Cited by in F6Publishing: 265] [Article Influence: 28.6] [Reference Citation Analysis]
508 Dai HT, Chen B, Tang KY, Zhang GY, Wen CY, Xiang XH, Yang JY, Guo Y, Lin R, Huang YH. Prognostic value of splenic volume in hepatocellular carcinoma patients receiving transarterial chemoembolization. J Gastrointest Oncol 2021;12:1141-51. [PMID: 34295563 DOI: 10.21037/jgo-21-226] [Reference Citation Analysis]
509 Huang M, Shen S, Cai H, Peng Z, Chiu WHK, Li ZP, Peng B, Feng ST. Regional liver function analysis with gadoxetic acid-enhanced MRI and virtual hepatectomy: prediction of postoperative short-term outcomes for HCC. Eur Radiol 2021;31:4720-30. [PMID: 33449173 DOI: 10.1007/s00330-020-07606-x] [Reference Citation Analysis]
510 Takeda A, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, Matsunaga K, Mizuno T, Yashiro K, Nisimura S, Kunieda E. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:372-379. [PMID: 23927053 DOI: 10.1111/jgh.12350] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis]
511 Abolhasani A, Heidari F, Noori S, Mousavi S, Abolhasani H. Cytotoxicity Evaluation of Dimethoxy and Trimethoxy Indanonic Spiroisoxazolines Against Cancerous Liver Cells. CCB 2020;14:38-47. [DOI: 10.2174/2212796813666190926112807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
512 Nishikawa H, Osaki Y, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Henmi S, Sakamoto A, Ishikawa T, Saito S, Kita R, Kimura T. Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2012; 18(12): 1379-1384 [PMID: 22493552 DOI: 10.3748/wjg.v18.i12.1379] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
513 Stevens CL, Awad A, Abbas SM, Watters DAK. Systematic review and meta-analysis of hepatic resection versus transarterial chemoembolization for solitary large hepatocellular carcinoma. HPB (Oxford) 2017;19:653-8. [PMID: 28427829 DOI: 10.1016/j.hpb.2017.03.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
514 Siddique O, Yoo ER, Perumpail RB, Perumpail BJ, Liu A, Cholankeril G, Ahmed A. The importance of a multidisciplinary approach to hepatocellular carcinoma. J Multidiscip Healthc. 2017;10:95-100. [PMID: 28360525 DOI: 10.2147/jmdh.s128629] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
515 Lucà MG, Nani R, Schranz M, De Giorgio M, Iegri C, Agazzi R, Sala F, Virotta G, Sarti D, Conte G, Pinelli D, Nicora C, Colledan M, Sironi S, Fagiuoli S. Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib. Future Oncology 2018;14:727-35. [DOI: 10.2217/fon-2017-0566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
516 Paul S, Dhamija E, Gamanagatti S, Sreenivas V, Yadav D, Jain S, Shalimar, Acharya S. Evaluation of tumor response to intra-arterial chemoembolization of hepatocellular carcinoma: Comparison of contrast-enhanced ultrasound with multiphase computed tomography. Diagnostic and Interventional Imaging 2017;98:253-60. [DOI: 10.1016/j.diii.2016.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
517 Lin L, Lu B, Yu J, Liu W, Zhou A. Serum miR-224 as a biomarker for detection of hepatocellular carcinoma at early stage. Clin Res Hepatol Gastroenterol. 2016;40:397-404. [PMID: 26724963 DOI: 10.1016/j.clinre.2015.11.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
518 Law JH, Tan JKH, Wong KYM, Ng WQ, Tan PS, Bonney GK, Iyer SG, Krishnakumar M, Kow WCA. Does persistent anti-HBc positivity influence the prognosis of HBsAg-negative hepatocellular carcinoma? comparative outcomes of anti-Hbc positive versus anti-Hbc negative non-B non-C HCC. HPB (Oxford) 2019;21:242-8. [PMID: 30087053 DOI: 10.1016/j.hpb.2018.07.012] [Reference Citation Analysis]
519 Odisio BC, Kaseb AO. Anti-angiogenic therapy in the setting of TACE: an elusive synergy? Lancet Gastroenterol Hepatol 2018;3:5-6. [PMID: 28988686 DOI: 10.1016/S2468-1253(17)30324-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
520 Lee JW, Yun M, Cho A, Han KH, Kim DY, Lee SM, Lee JD. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. Ann Nucl Med. 2015;29:400-408. [PMID: 25652647 DOI: 10.1007/s12149-015-0956-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
521 Soresi M, Terranova A, Licata A, Serruto A, Montalto G, Brancatelli G, Giannitrapani L. Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns. Biomed Res Int 2017;2017:4932759. [PMID: 28638828 DOI: 10.1155/2017/4932759] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
522 Morise Z. Laparoscopic liver resection for the patients with hepatocellular carcinoma and chronic liver disease. Transl Gastroenterol Hepatol 2018;3:41. [PMID: 30148226 DOI: 10.21037/tgh.2018.07.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
523 Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Ignacio Bilbao J, Maria Ettorre G, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Thorsten Hoffmann R, Izzo F, Iñarrairaegui M, Ludovico Maini C, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Franz Jakobs T, Lastoria S; on behalf of the European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology 2011;54:868-78. [DOI: 10.1002/hep.24451] [Cited by in Crossref: 401] [Cited by in F6Publishing: 366] [Article Influence: 40.1] [Reference Citation Analysis]
524 Cheng J, Xie HY, Xu X, Wu J, Wei X, Su R, Zhang W, Lv Z, Zheng S, Zhou L. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. Cancer Lett. 2011;310:35-45. [PMID: 21763068 DOI: 10.1016/j.canlet.2011.06.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 7.4] [Reference Citation Analysis]
525 Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol 2015; 21(36): 10327-10335 [PMID: 26420959 DOI: 10.3748/wjg.v21.i36.10327] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 50] [Article Influence: 9.0] [Reference Citation Analysis]
526 Lim TS, Kim DY, Han KH, Kim HS, Shin SH, Jung KS, Kim BK, Kim SU, Park JY, Ahn SH. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol. 2016;51:344-353. [PMID: 26340708 DOI: 10.3109/00365521.2015.1082190] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
527 Cortese S, Morales J, Martín L, Kayser S, Colón A, Ramón E, Tellado JM. Resección hepática con trombectomía en el tratamiento del carcinoma hepatocelular con invasión vascular macroscópica. Cirugía Española 2020;98:9-17. [DOI: 10.1016/j.ciresp.2019.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
528 Sprinzl MF, Puschnik A, Schlitter AM, Schad A, Ackermann K, Esposito I, Lang H, Galle PR, Weinmann A, Heikenwälder M, Protzer U. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. Journal of Hepatology 2015;62:863-70. [DOI: 10.1016/j.jhep.2014.11.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
529 Yuan Z, Wang Y, Hu C, Gao W, Zheng J, Li W. Efficacy of Percutaneous Thermal Ablation Combined With Transarterial Embolization for Recurrent Hepatocellular Carcinoma After Hepatectomy and a Prognostic Nomogram to Predict Survival. Technol Cancer Res Treat 2018;17:1533033818801362. [PMID: 30244651 DOI: 10.1177/1533033818801362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
530 Takahashi K, Ofuji K, Hiramatsu K, Nosaka T, Naito T, Matsuda H, Endo K, Higuchi M, Ohtani M, Nemoto T, Nakamoto Y. Circulating tumor cells detected with a microcavity array predict clinical outcome in hepatocellular carcinoma. Cancer Med 2021;10:2300-9. [PMID: 33675149 DOI: 10.1002/cam4.3790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
531 Chang PY, Chung CH, Chang WC, Lin CS, Lin HH, Dai MS, Ho CL, Chien WC. The effect of propranolol on the prognosis of hepatocellular carcinoma: A nationwide population-based study. PLoS One 2019;14:e0216828. [PMID: 31125347 DOI: 10.1371/journal.pone.0216828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
532 Uyei J, Taddei TH, Kaplan DE, Chapko M, Stevens ER, Braithwaite RS. Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. PLoS One 2019;14:e0221614. [PMID: 31449554 DOI: 10.1371/journal.pone.0221614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
533 Samonakis DN, Kouroumalis EA. Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol 2017; 9(2): 80-90 [PMID: 28144389 DOI: 10.4254/wjh.v9.i2.80] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
534 Morisco F, Guarino M, Valvano MR, Auriemma F, Farinati F, Giannini EG, Ciccarese F, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Benvengù L, Gasbarrini A, Svegliati Baroni G, Foschi FG, Biasini E, Masotto A, Virdone R, Marra F, Caporaso N, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Metabolic disorders across hepatocellular carcinoma in Italy. Liver Int 2018;38:2028-39. [PMID: 29745475 DOI: 10.1111/liv.13877] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
535 Zhang C, Chen B, Jiao A, Li F, Sun N, Zhang G, Zhang J. miR-663a inhibits tumor growth and invasion by regulating TGF-β1 in hepatocellular carcinoma. BMC Cancer 2018;18:1179. [PMID: 30486878 DOI: 10.1186/s12885-018-5016-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
536 Kroh A, Walter J, Schüler H, Nolting J, Eickhoff R, Heise D, Neumann UP, Cramer T, Ulmer TF, Fragoulis A. A Newly Established Murine Cell Line as a Model for Hepatocellular Cancer in Non-Alcoholic Steatohepatitis. Int J Mol Sci 2019;20:E5658. [PMID: 31726709 DOI: 10.3390/ijms20225658] [Reference Citation Analysis]
537 Wu CF, Wu YJ, Liang PC, Wu CH, Peng SF, Chiu HW. Disease-free survival assessment by artificial neural networks for hepatocellular carcinoma patients after radiofrequency ablation. J Formos Med Assoc. 2017;116:765-773. [PMID: 28117199 DOI: 10.1016/j.jfma.2016.12.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
538 Xu Y, Zhang Z, Xu D, Yang X, Zhou L, Zhu Y. Identification and integrative analysis of ACLY and related gene panels associated with immune microenvironment reveal prognostic significance in hepatocellular carcinoma. Cancer Cell Int 2021;21:409. [PMID: 34344378 DOI: 10.1186/s12935-021-02108-2] [Reference Citation Analysis]
539 Wang WH, Wang Z, Wu JX, Zhang T, Rong WQ, Wang LM, Jin J, Wang SL, Song YW, Liu YP, Ren H, Fang H, Wang WQ, Liu XF, Yu ZH, Li YX. Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels. Liver Int. 2015;35:2603-2610. [PMID: 25939444 DOI: 10.1111/liv.12857] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
540 Li X, Wu YS, Chen D, Lin H. Laparoscopic hepatectomy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Manag Res 2019;11:5711-24. [PMID: 31417314 DOI: 10.2147/CMAR.S189777] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
541 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
542 Liu Z, Lin Y, Zhang J, Zhang Y, Li Y, Liu Z, Li Q, Luo M, Liang R, Ye J. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38:447. [PMID: 31684985 DOI: 10.1186/s13046-019-1412-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 23.5] [Reference Citation Analysis]
543 Cheng CH, Lee CF, Wu TH, Chan KM, Chou HS, Wu TJ, Yu MC, Chen TC, Lee WC, Chen MF. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol. 2011;9:114. [PMID: 21958080 DOI: 10.1186/1477-7819-9-114] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
544 Sun Q, Li J, Jin B, Wang T, Gu J. Evaluation of miR-331-3p and miR-23b-3p as serum biomarkers for hepatitis c virus-related hepatocellular carcinoma at early stage. Clin Res Hepatol Gastroenterol 2020;44:21-8. [PMID: 31053500 DOI: 10.1016/j.clinre.2019.03.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
545 Kohli A, Murphy AA, Agarwal C, Shivakumar B, Kottilil S, Polis MA, Subramanian GM, Midha V, Goyal O, Desai S, Sood A, Shah S. HCC surveillance results in earlier HCC detection: results from an Indian cohort. Springerplus 2014;3:610. [PMID: 25392781 DOI: 10.1186/2193-1801-3-610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
546 Zhang R, Chen J, Jiang Y, Wang J, Chen S. Prognostic nomogram for hepatocellular carcinoma with fibrosis of varying degrees: a retrospective cohort study. Ann Transl Med 2020;8:1429. [PMID: 33313174 DOI: 10.21037/atm-20-3267] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
547 Kokabi N, Xing M, Duszak R Jr, Duszak R Jr, Howard DH, Applegate KE, Camacho JC, Kim HS. Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study. Future Oncol 2016;12:183-98. [PMID: 26690268 DOI: 10.2217/fon.15.242] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
548 Liu F, Li F, Luo L, Yang H, Wei Y, Wang W, Yan L, Wen T, Yang J, Li B. Genetic variants in cell death pathway genes and HBV-related hepatocellular carcinoma among a Chinese Han population. Apoptosis 2017;22:1035-47. [DOI: 10.1007/s10495-017-1385-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
549 Cheng JW, Lv Y. New progress of non-surgical treatments for hepatocellular carcinoma. Med Oncol 2013;30:381. [PMID: 23292867 DOI: 10.1007/s12032-012-0381-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
550 Bouda D, Lagadec M, Alba CG, Barrau V, Dioguardi Burgio M, Moussa N, Vilgrain V, Ronot M. Imaging review of hepatocellular carcinoma after thermal ablation: The good, the bad, and the ugly: Imaging of HCC After Thermal Ablation. J Magn Reson Imaging 2016;44:1070-90. [DOI: 10.1002/jmri.25369] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
551 Titano J, Voutsinas N, Kim E. The Role of Radioembolization in Bridging and Downstaging Hepatocellular Carcinoma to Curative Therapy. Semin Nucl Med 2019;49:189-96. [PMID: 30954184 DOI: 10.1053/j.semnuclmed.2019.01.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
552 Harada N, Shirabe K, Maeda T, Kayashima H, Ishida T, Maehara Y. Surgical Resection for Hepatocellular Carcinoma with Concomitant Esophageal Varices. World J Surg 2015;39:2510-8. [DOI: 10.1007/s00268-015-3110-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
553 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
554 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 251] [Article Influence: 35.3] [Reference Citation Analysis]
555 Lassandro G, Picchi SG, Bianco A, Di Costanzo G, Coppola A, Ierardi AM, Lassandro F. Effectiveness and safety in radiofrequency ablation of pulmonary metastases from HCC: a five years study. Med Oncol. 2020;37:25. [PMID: 32166529 DOI: 10.1007/s12032-020-01352-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
556 Li J, Jin B, Wang T, Li W, Wang Z, Zhang H, Song Y, Li N. Serum microRNA expression profiling identifies serum biomarkers for HCV-related hepatocellular carcinoma. Cancer Biomark 2019;26:501-12. [PMID: 31658041 DOI: 10.3233/CBM-181970] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 17.0] [Reference Citation Analysis]
557 Jia AY, Popovic A, Mohan AA, Zorzi J, Griffith P, Kim AK, Anders RA, Burkhart RA, Lafaro K, Georgiades C, Azad NS, Liddell RP, Baretti M, Kamel IR, Narang A, Yarchoan M, Meyer J. Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control 2021;28:10732748211009945. [PMID: 33882707 DOI: 10.1177/10732748211009945] [Reference Citation Analysis]
558 Wang R, Yin C, Li XX, Yang XZ, Yang Y, Zhang MY, Wang HY, Zheng XF. Reduced SOD2 expression is associated with mortality of hepatocellular carcinoma patients in a mutant p53-dependent manner. Aging (Albany NY) 2016;8:1184-200. [PMID: 27221200 DOI: 10.18632/aging.100967] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
559 Yang W, Wang D, Huang L, Chen Y, Wen S, Hong Q, Kang D. Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach. Asian Pac J Cancer Prev 2018;19:2043-55. [PMID: 30139041 DOI: 10.22034/APJCP.2018.19.8.2043] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
560 Zhong JH, Xiang BD, Gong WF, Ke Y, Mo QG, Ma L, Liu X, Li LQ. Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One. 2013;8:e68193. [PMID: 23874536 DOI: 10.1371/journal.pone.0068193] [Cited by in Crossref: 97] [Cited by in F6Publishing: 107] [Article Influence: 12.1] [Reference Citation Analysis]
561 Yoon JH, Lee WJ, Kim SM, Kim KT, Cho SB, Kim HJ, Ko YS, Kook HY, Jun CH, Choi SK, Kim BS, Cho SY, You HS, Lee Y, Son S. Simple parameters predicting extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Sci Rep 2021;11:12984. [PMID: 34155324 DOI: 10.1038/s41598-021-92503-6] [Reference Citation Analysis]
562 Liao B, Liang H, Chen J, Liu Q, Zhang B, Chen X. Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase. Tumor Biol 2015;36:9347-56. [DOI: 10.1007/s13277-015-3497-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
563 Cha MJ, Lee MW, Cha DI, Kim JH, Rhim H, Cho YK, Kim YJ, Choi D, Kim YS, Lim HK. Size discrepancy between sonographic and computed tomographic/magnetic resonance imaging measurement of hepatocellular carcinoma: the necessity of tumor size measurement standardization. J Ultrasound Med 2013;32:1703-9. [PMID: 24065250 DOI: 10.7863/ultra.32.10.1703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
564 Cha H, Yoon HI, Lee IJ, Koom WS, Han KH, Seong J. Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma. J Radiat Res. 2013;54:1069-1077. [PMID: 23633620 DOI: 10.1093/jrr/rrt034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
565 Li MX, Zhao H, Bi XY, Li ZY, Huang Z, Han Y, Zhou JG, Zhao JJ, Zhang YF, Cai JQ. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma: Validation in a Chinese cohort. Hepatol Res. 2017;47:731-741. [PMID: 27558521 DOI: 10.1111/hepr.12796] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
566 Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Stauber R, Grünberger B, Müller C, Kölblinger C. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology. 2012;263:590-599. [PMID: 22438359 DOI: 10.1148/radiol.12111550] [Cited by in Crossref: 126] [Cited by in F6Publishing: 131] [Article Influence: 14.0] [Reference Citation Analysis]
567 Giunchedi P, Maestri M, Gavini E, Dionigi P, Rassu G. Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1. Expert Opin Drug Deliv 2013;10:679-90. [PMID: 23406440 DOI: 10.1517/17425247.2013.770733] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
568 Zhong JH, Wu FX, Li H. Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma. Tumour Biol 2014;35:8355-8. [PMID: 25195949 DOI: 10.1007/s13277-014-2571-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
569 Wan G, Gao F, Chen J, Li Y, Geng M, Sun L, Liu Y, Liu H, Yang X, Wang R. Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma. BMC Cancer. 2017;17:91. [PMID: 28143427 DOI: 10.1186/s12885-017-3062-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
570 Wei Y, Chen X, Liang C, Ling Y, Yang X, Ye X, Zhang H, Yang P, Cui X, Ren Y, Xin X, Li H, Wang R, Wang W, Jiang F, Liu S, Ding J, Zhang B, Li L, Wang H. A Noncoding Regulatory RNAs Network Driven by Circ-CDYL Acts Specifically in the Early Stages Hepatocellular Carcinoma. Hepatology 2020;71:130-47. [PMID: 31148183 DOI: 10.1002/hep.30795] [Cited by in Crossref: 62] [Cited by in F6Publishing: 72] [Article Influence: 31.0] [Reference Citation Analysis]
571 Gish RG, Lencioni R, Di Bisceglie AM, Raoul J, Mazzaferro V. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;6:173-85. [DOI: 10.1586/egh.11.105] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
572 Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Satani M, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group Of Japan. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. Oncotarget 2016;7:64400-9. [PMID: 27462865 DOI: 10.18632/oncotarget.10794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
573 Villanueva A, Newell P, Hoshida Y. Inherited hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2010;24:725-34. [PMID: 20955973 DOI: 10.1016/j.bpg.2010.07.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
574 Masalaite L, Valantinas J, Stanaitis J. Endoscopic ultrasound findings predict the recurrence of esophageal varices after endoscopic band ligation: a prospective cohort study. Scand J Gastroenterol. 2015;50:1322-1330. [PMID: 25956657 DOI: 10.3109/00365521.2015.1043640] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
575 Cong M, Ou X, Huang J, Long J, Li T, Liu X, Wang Y, Wu X, Zhou J, Sun Y, Shang Q, Chen G, Ma H, Xie W, Piao H, Yang Y, Gao Z, Xu X, Tan Z, Chen C, Zeng N, Wu S, Kong Y, Liu T, Wang P, You H, Jia J, Zhuang H. A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. OMICS 2020;24:415-23. [PMID: 32522092 DOI: 10.1089/omi.2020.0055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
576 Rossi S, Ravetta V, Rosa L, Ghittoni G, Viera FT, Garbagnati F, Silini EM, Dionigi P, Calliada F, Quaretti P. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. Hepatology. 2011;53:136-147. [PMID: 20967759 DOI: 10.1002/hep.23965] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 9.6] [Reference Citation Analysis]
577 Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist. 2010;15 Suppl 4:42-52. [PMID: 21115580 DOI: 10.1634/theoncologist.2010-s4-42] [Cited by in Crossref: 102] [Cited by in F6Publishing: 61] [Article Influence: 10.2] [Reference Citation Analysis]
578 Koulakian H, Allaham W, Vilgrain V, Ronot M. Non-measurable infiltrative HCC: is post-contrast attenuation on CT a sign of tumor response? Eur Radiol 2019;29:4389-99. [PMID: 30413965 DOI: 10.1007/s00330-018-5805-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
579 Liu X, Han C, Liao X, Yu L, Zhu G, Su H, Qin W, Lu S, Ye X, Peng T. Genetic variants in the exon region of versican predict survival of patients with resected early-stage hepatitis B virus-associated hepatocellular carcinoma. Cancer Manag Res 2018;10:1027-36. [PMID: 29765250 DOI: 10.2147/CMAR.S161906] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
580 Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol 2014; 20(12): 3100-3111 [PMID: 24696597 DOI: 10.3748/wjg.v20.i12.3100] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
581 Chang KH, Hwang ZA, Chang PY, Lin HH, Shih YL, Chang WC, Huang GS, Hsu HH. Predictive imaging for tumor response to drug-eluting microsphere transarterial chemoembolization in patients with BCLC-C advanced hepatocellular carcinoma. Sci Rep 2019;9:20032. [PMID: 31882969 DOI: 10.1038/s41598-019-56545-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
582 Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Korenaga M, Mizokami M, Narimatsu H. Serum WFA + -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int 2016;36:293-301. [DOI: 10.1111/liv.12907] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
583 Arslanoglu A, Seyal AR, Sodagari F, Sahin A, Miller FH, Salem R, Yaghmai V. Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review. American Journal of Roentgenology 2016;207:W88-98. [DOI: 10.2214/ajr.15.15490] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 3.4] [Reference Citation Analysis]
584 Shrager B, Jibara GA, Tabrizian P, Schwartz ME, Labow DM, Hiotis S. Resection of large hepatocellular carcinoma (≥10 cm): A unique western perspective: Resection of Large HCC in the West. J Surg Oncol 2013;107:111-7. [DOI: 10.1002/jso.23246] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
585 Zheng T, Chen M, Han S, Zhang L, Bai Y, Fang X, Ding SZ, Yang Y. Plasma minichromosome maintenance complex component 6 is a novel biomarker for hepatocellular carcinoma patients. Hepatol Res. 2014;44:1347-1356. [PMID: 24451028 DOI: 10.1111/hepr.12303] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
586 Liu X, Jiang W, Aucejo F, Kim R, Miller C, Byrne M, Lopez R, Yerian L. Insulin-like growth factor I receptor β expression in hepatocellular carcinoma. Hum Pathol. 2011;42:882-891. [PMID: 21292299 DOI: 10.1016/j.humpath.2010.10.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
587 Fang KC, Kao WY, Su CW, Chen PC, Lee PC, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. Liver Cancer. 2018;7:335-358. [PMID: 30488023 DOI: 10.1159/000487407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
588 Wei Q, Tian H, Luo H, Zhang Y, Deng Y, Yao J, Li H, Chen G, Yang Y. Better prognosis of hepatic resection combined with antiviral therapy for HBV-related hepatocellular carcinoma with BCLC Stage B/C. Asian Journal of Surgery 2017;40:453-62. [DOI: 10.1016/j.asjsur.2016.03.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
589 Uhlig J, Sellers CM, Stein SM, Kim HS. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. Eur Radiol. 2019;29:2679-2689. [PMID: 30560364 DOI: 10.1007/s00330-018-5902-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
590 Lee A, Rode A, Nicoll A, Maczurek AE, Lim L, Lim S, Angus P, Kronborg I, Arachchi N, Gorelik A, Liew D, Warner FJ, McCaughan GW, McLennan SV, Shackel NA. Circulating CD147 predicts mortality in advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2016;31:459-66. [PMID: 26312403 DOI: 10.1111/jgh.13148] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
591 Feliu J, Sastre J, Maurel J, Isla D. Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines. Clin Transl Oncol 2011;13:536-44. [PMID: 21821487 DOI: 10.1007/s12094-011-0694-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
592 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1921] [Article Influence: 707.3] [Reference Citation Analysis]
593 Liu Y, Xue D, Zhang X, Gao F, Sun L, Yang X, Li Y, Zhang Q, Zhu B, Niu S, Huang Y, Hu Y, Wang X. Nomogram for Individualized Prediction of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis on Conservative Treatment. Biomed Res Int 2020;2020:1473718. [PMID: 32149077 DOI: 10.1155/2020/1473718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
594 Bruix J, Fuster J. A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations? An Observational Study of the HCC East-West Study Group. Ann Surg 2015;262:e30. [PMID: 24374519 DOI: 10.1097/SLA.0000000000000381] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
595 Ikuta S, Aihara T, Yamanaka N. Efficacy of sequential sorafenib plus hepatic arterial infusion chemotherapy in patients with Barcelona Clinic Liver Cancer stage B and C hepatocellular carcinoma: a retrospective single-institution study. Contemp Oncol (Pozn) 2018;22:165-71. [PMID: 30455588 DOI: 10.5114/wo.2018.78948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
596 Amini A, Gamblin TC. Palliation: treating patients with inoperable biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23:383-397. [PMID: 24560116 DOI: 10.1016/j.soc.2013.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
597 Lin W, Zhong M, Liang S, Chen Y, Liu D, Yin Z, Cao Q, Wang C, Ling C. Emodin inhibits migration and invasion of MHCC-97H human hepatocellular carcinoma cells. Exp Ther Med 2016;12:3369-74. [PMID: 27882165 DOI: 10.3892/etm.2016.3793] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
598 Sanuki N, Takeda A, Oku Y, Eriguchi T, Nishimura S, Aoki Y, Kunieda E. Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma. Hepatol Res. 2014;Epub ahead of print. [PMID: 24976460 DOI: 10.1111/hepr.12383] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
599 Chai W, Tian G, Jiang T. Percutaneous Irreversible Electroporation for Portal Vein Tumor Thrombus: A Case Report. Ultrasound Q 2017;33:296-9. [PMID: 28650421 DOI: 10.1097/RUQ.0000000000000305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
600 Li L, Diao W, Zen K. Micro-ribonucleic acids: potential noninvasive biomarkers for hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:21-33. [PMID: 27508173 DOI: 10.2147/JHC.S44463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
601 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
602 Mokdad AA, Singal AG, Yopp AC. Advances in Local and Systemic Therapies for Hepatocellular Cancer. Curr Oncol Rep 2016;18:9. [PMID: 26769114 DOI: 10.1007/s11912-015-0494-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
603 Cha H, Park HC, Yu JI, Kim TH, Nam TK, Yoon SM, Yoon WS, Kim JW, Kim MS, Jang HS, Choi Y, Kim JH, Kay CS, Jung I, Seong J. Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07). Cancer Res Treat. 2017;49:61-69. [PMID: 27338036 DOI: 10.4143/crt.2016.097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
604 Chan KM, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, Yu MC, Lee WC. The Preference for Anterior Approach Major Hepatectomy: Experience Over 3 Decades and a Propensity Score-Matching Analysis in Right Hepatectomy for Hepatocellular Carcinoma. Medicine. (Baltimore). 2015;94:e1385. [PMID: 26313778 DOI: 10.1097/md.0000000000001385] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
605 Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, Delarocque-Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, Gore C, Lok AS, Manns M, Marcellin P, Papatheodoridis G, Peterle A, Prati D, Piorkowsky N, Rizzetto M, Roudot-Thoraval F, Soriano V, Thomas HC, Thursz M, Valla D, van Damme P, Veldhuijzen IK, Wedemeyer H, Wiessing L, Zanetti AR, Janssen HL. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat. 2011;18 Suppl 1:1-16. [PMID: 21824223 DOI: 10.1111/j.1365-2893.2011.01499.x] [Cited by in Crossref: 159] [Cited by in F6Publishing: 155] [Article Influence: 15.9] [Reference Citation Analysis]
606 Langenbach MC. RFA vs resection of HCC: exploring the past to improve the future. Eur Radiol 2019;29:2677-8. [PMID: 30715586 DOI: 10.1007/s00330-019-6000-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
607 Liu Y, Wang Z, Cao Y, Zhang G, Chen W, Jiang C. Preoperative inflammation-based markers predict early and late recurrence of hepatocellular carcinoma after curative hepatectomy. Hepatobiliary & Pancreatic Diseases International 2016;15:266-74. [DOI: 10.1016/s1499-3872(16)60094-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
608 Baffy G. Decoding multifocal hepatocellular carcinoma: an opportune pursuit. Hepatobiliary Surg Nutr 2015;4:206-10. [PMID: 26151061 DOI: 10.3978/j.issn.2304-3881.2014.12.05] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
609 Abbass MA, Ahmad SA, Mahalingam N, Krothapalli KS, Masterson JA, Rao MB, Barthe PG, Mast TD. In vivo ultrasound thermal ablation control using echo decorrelation imaging in rabbit liver and VX2 tumor. PLoS One 2019;14:e0226001. [PMID: 31805129 DOI: 10.1371/journal.pone.0226001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
610 Jang ES, Yoon JH, Chung JW, Cho EJ, Yu SJ, Lee JH, Kim YJ, Lee HS, Kim CY. Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. J Cancer Res Clin Oncol. 2013;139:635-643. [PMID: 23283527 DOI: 10.1007/s00432-012-1364-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
611 Lin CL, Kao JH. Optimal management of hepatocellular carcinoma: challenges and opportunities. J Gastroenterol Hepatol 2010;25:1336-8. [PMID: 20659219 DOI: 10.1111/j.1440-1746.2010.06373.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
612 Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, Ladrón de Guevara L, Papandreou C. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. Radiology. 2016;279:630-640. [PMID: 26744927 DOI: 10.1148/radiol.2015150667] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 12.0] [Reference Citation Analysis]
613 Huang Y, Shen Q, Bai HX, Wu J, Ma C, Shang Q, Hunt SJ, Karakousis G, Zhang PJ, Zhang Z. Comparison of Radiofrequency Ablation and Hepatic Resection for the Treatment of Hepatocellular Carcinoma 2 cm or Less. Journal of Vascular and Interventional Radiology 2018;29:1218-1225.e2. [DOI: 10.1016/j.jvir.2018.04.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
614 Sheng RF, Zeng MS, Ren ZG, Ye SL, Zhang L, Chen CZ. Intrahepatic distant recurrence following complete radiofrequency ablation of small hepatocellular carcinoma: risk factors and early MRI evaluation. Hepatobiliary Pancreat Dis Int 2015;14:603-12. [PMID: 26663008 DOI: 10.1016/s1499-3872(15)60390-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
615 Chen L, Ni C, Chen S, Cao J, Zhu H, Guo J, Zhu G, Zhong B, Ding W, He S, Deng G, Teng G. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients. Journal of Vascular and Interventional Radiology 2016;27:1288-97. [DOI: 10.1016/j.jvir.2015.12.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
616 Chen TM, Lin CC, Huang PT, Wen CF. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2011;26:858-65. [PMID: 21251068 DOI: 10.1111/j.1440-1746.2011.06664.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 6.5] [Reference Citation Analysis]
617 Barone C, Koeberle D, Metselaar H, Parisi G, Sansonno D, Spinzi G. Multidisciplinary approach for HCC patients: hepatology for the oncologists. Ann Oncol. 2013;24 Suppl 2:ii15-ii23. [PMID: 23715939 DOI: 10.1093/annonc/mdt053] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
618 Liu PH, Su CW, Hsu CY, Hsia CY, Lee YH, Huang YH, Lee RC, Lin HC, Huo TI. Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. PLoS One. 2016;11:e0155588. [PMID: 27176037 DOI: 10.1371/journal.pone.0155588] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
619 Huang J, Xu L, Luo Y, He F, Zhang Y, Chen M. The inflammation-based scores to predict prognosis of patients with hepatocellular carcinoma after hepatectomy. Med Oncol. 2014;31:883. [PMID: 24535607 DOI: 10.1007/s12032-014-0883-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
620 Waly Raphael S, Yangde Z, Yuxiang C. Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol 2012;2012:421673. [PMID: 22655206 DOI: 10.5402/2012/421673] [Cited by in Crossref: 25] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
621 Gans JH, Lipman J, Golowa Y, Kinkhabwala M, Kaubisch A. Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in? Seminars in Nuclear Medicine 2019;49:170-81. [DOI: 10.1053/j.semnuclmed.2019.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
622 Tang Q, Huang W, Liang J, Xue J. Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study. Front Oncol 2021;11:646410. [PMID: 34307128 DOI: 10.3389/fonc.2021.646410] [Reference Citation Analysis]
623 Choi JH, Chung WJ, Bae SH, Song DS, Song MJ, Kim YS, Yim HJ, Jung YK, Suh SJ, Park JY, Kim DY, Kim SU, Cho SB. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2018;82:469-478. [PMID: 29982870 DOI: 10.1007/s00280-018-3638-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
624 Tremosini S, Reig M, de Lope CR, Forner A, Bruix J. Treatment of early hepatocellular carcinoma: Towards personalized therapy. Dig Liver Dis. 2010;42 Suppl 3:S242-S248. [PMID: 20547310 DOI: 10.1016/s1590-8658(10)60512-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
625 Wan L, Dong DH, Wu XN, Ding HF, Lu Q, Tian Y, Zhang XF, Li W. Single Large Nodule (>5 cm) Prognosis in Hepatocellular Carcinoma: Kinship with Barcelona Clinic Liver Cancer (BCLC) Stage A or B? Med Sci Monit 2020;26:e926797. [PMID: 33060558 DOI: 10.12659/MSM.926797] [Reference Citation Analysis]
626 Liu C, Duan LG, Lu WS, Yan LN, Xiao GQ, Jiang L, Yang J, Yang JY. Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems. PLoS One 2014;9:e103228. [PMID: 25133493 DOI: 10.1371/journal.pone.0103228] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
627 Zou X, Fan W, Xue M, Li J. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. Cancer Manag Res 2021;13:4013-29. [PMID: 34040442 DOI: 10.2147/CMAR.S304591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
628 Zhang Y, Huang G, Wang Y, Liang L, Peng B, Fan W, Yang J, Huang Y, Yao W, Li J. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience. Oncologist 2016;21:1442-9. [PMID: 27486202 DOI: 10.1634/theoncologist.2016-0094] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
629 Hsu KF, Yu JC, Yang CW, Chen BC, Chen CJ, Chan DC, Fan HL, Chen TW, Shih YL, Hsieh TY, Hsieh CB. Long-term outcomes in elderly patients with resectable large hepatocellular carcinoma undergoing hepatectomy. Surg Oncol 2018;27:595-601. [PMID: 30217323 DOI: 10.1016/j.suronc.2018.07.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
630 Shen H, Zheng S, Chen R, Jin X, Xu X, Jing C, Lin J, Zhang J, Zhang M, Zhang L, Xie X, Guo K, Ren Z, Lin S, Zhang B. Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization: A retrospective analysis of 509 cases. Medicine (Baltimore) 2017;96:e7438. [PMID: 28700480 DOI: 10.1097/MD.0000000000007438] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
631 Sangiovanni A, Triolo M, Iavarone M, Forzenigo LV, Nicolini A, Rossi G, La Mura V, Colombo M, Lampertico P. Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. Liver Int 2018;38:1624-34. [DOI: 10.1111/liv.13888] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
632 Fan Z, He J, Fu T, Zhang W, Yang G, Qu X, Liu R, Lv L, Wang J. Arsenic trioxide inhibits EMT in hepatocellular carcinoma by promoting lncRNA MEG3 via PKM2. Biochemical and Biophysical Research Communications 2019;513:834-40. [DOI: 10.1016/j.bbrc.2019.04.081] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]